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The treatment of cancer with proton radiation therapy was first suggested in 1946 followed by the first 
treatments in the 1950s. As of 2020, almost 200,000 patients have been treated with proton beams 
worldwide and the number of operating proton therapy facilities will soon reach one hundred. Proton 
therapy has long moved from research institutions into hospital-based facilities that are increasingly 
being utilized with workflows similar to conventional radiation therapy. 
While proton therapy has become mainstream and has established itself as a treatment option for many 
cancers, it is still an area of active research for various reasons: the advanced dose shaping capabilities 
of proton therapy cause susceptibility to uncertainties, the high degrees of freedom in dose delivery offer 
room for further improvements, the limited experience and understanding of optimizing pencil beam 
scanning, and the biological effects differ from photon radiation. In addition to these challenges and 
opportunities currently being investigated, there is an economic aspect because proton therapy treatments 
are, on average, still more expensive compared to conventional photon based treatment options. 
This roadmap highlights the current state and future direction in proton therapy categorized into four 
different themes, “improving efficiency”, “improving planning and delivery”, “improving imaging”, and 
“improving patient selection”.  
 
Introduction to the Proton Therapy Roadmap 
Harald Paganetti and Tony Lomax 
The dosimetric advantages of proton radiation therapy compared to ‘conventional’ photon radiation 
therapy were first outlined by Wilson in 1946 (Wilson, 1946). He presented the idea of utilizing the finite 
range of proton beams for treating targets deep within healthy tissue, and was thus the first to describe 
the potential of proton beams for medical use. Wilson’s suggestion to use protons was based on the well-
known physics of protons as they slow down while penetrating tissue, causing the Bragg peak and 
completely stopping in the patient.  
While the advantage of protons was seen from a physics (dosimetric) perspective, any new radiation 
treatment technology has to find acceptance amongst clinicians by demonstrating that the improved dose 
distribution leads to a more favorable treatment outcome (Suit et al., 1975). When proton therapy was 
first introduced it was of interest mainly because it showed dose conformity far superior to any type of 
conventional photon radiation therapy at the time (Suit and Goitein, 1974; Suit et al., 1977). The 
difference in target dose conformity between protons and photons, at least at high doses, has however 
largely disappeared since the early days of proton therapy (at least for regularly shaped targets), mainly 
due to the development of intensity-modulated photon therapy and its extension to rotational therapies. 
Today, it is quite feasible to reach high-dose conformity to the target with photons that is comparable to 
the one achievable with protons, albeit at the expense of using a larger number of beams. However, the 
integral dose (the total energy deposited in the patient) is always lower with proton beams (by a factor 
of at least 2-3 (Lomax et al., 1999)), i.e. proton treatments avoid the ‘dose bath’ to healthy tissue that 
patients are exposed to with photon techniques. Indeed, there is a limit to further improving and shaping 
photon generated dose distributions because the total energy deposited in the patient, and thus to critical 
structures, cannot be reduced but only distributed differently. Proton radiation therapy, on the other hand, 
can still achieve further improvements through the use of scanning-beam technology and intensity-
modulated proton therapy. 
Proton therapy is already an established treatment option for many tumor types and sites. For instance, 
it is well recognized that protons are extremely valuable to treat tumors close to critical structures, e.g., 










































































for head-and-neck treatments (Chan and Liebsch, 2008). In the pediatric patient population however, the 
impact of the decreased total absorbed energy in the patient with protons seems most significant. The 
overall quality-of-life and reduction of secondary effects is particularly important and the reduction in 
overall normal tissue dose has proven to be relevant for short and long term toxicities (Indelicato et al. 
2019, Xiang et al. 2020). One prime example is the treatment of medulloblastoma, where treatment with 
photon radiation therapy invariably causes significant dose to the heart, lung and abdominal tissues, as 
well as organs at risk in the cranium, something that can largely be avoided using protons (Kamran et 
al. 2018). The reduced integral dose with protons is also beneficial when radiation is combined 
concurrently with chemotherapy (Baumann et al. 2019). Nevertheless, there are still many circumstances 
and treatment sites where the advantage of protons appears to be marginal at best (Lee et al., 1994; Liao 
et al., 2016). Thus, it is debatable whether the dosimetric advantages of proton therapy are clinically 
significant for all treatment sites, warranting the various randomized clinical trials comparing protons 
and photons that are currently being conducted for sites such as breast, prostate, lung, and many others. 
There is thus much that still needs to be done to fully exploit the physical advantages of protons. As 
such, this roadmap focusses on physics and biology aspects that are currently, or should be in the future, 
the subject of major research and development projects. Other aspects that are already clinical reality or 
are well on their way to being clinical standards (e.g. Monte Carlo based dosimetry for planning and 
quality assurance) will not be addressed in detail. Furthermore, as most centers will be treating with 
beam scanning in the near future, passively scattered proton therapy is not discussed, even if many of 
the innovations highlighted in this roadmap are independent of the delivery method. 
The targeted audience for this roadmap are the readers of Physics in Medicine and Biology. Accordingly, 
except when relevant in the context, we are not discussing specific clinical applications of proton 
therapy. Similarly, although the health economics and resulting societal impacts of treatment with proton 
therapy is a highly interesting and controversial field, we have not included articles specifically related 
to this or other societal impacts. With that said of course, many of the topics discussed here, such as 
efficiency gains and identifying those patients most likely to benefit from reduced side effects or 
improved tumor control with proton therapy, would be expected to reduce overall health care costs.This 
roadmap instead highlights the current state and future direction of proton therapy from the physics and 
biology aspects, in which we have categorized the articles into four different themes, “improving 
efficiency”, “improving planning and delivery”, “improving imaging”, and “improving patient 
selection”.  
Improving efficiency 
Proton therapy is a currently expensive treatment modality. Nevertheless, the cost of a proton treatment 
is expected to decrease with increasing number of facilities, and many developments in accelerator 
technology are focusing on lowering initial investments when acquiring a proton therapy facility by 
providing single room treatment facilities or even facilities without a gantry. Extensive work is being 
done also on improving beam delivery efficiency to reduce operating costs. These developments should 
of course not compromise the achievable dose conformity. 
As such we have four roadmap contributions dealing with treatment efficiency; “Cost reduction by 
optimizing accelerator technology”, “Technology for delivery efficiency”, “Delivery technology”, and 
“Efficient treatment room utilization”. While not directly evident, roadmap contributions in other 
sections such as those concerning the biological effectiveness of proton beams as well as biomarkers 
may also contribute to improved cost effectiveness in the future. For instance, identifying patients most 
likely to benefit from reduced side effects or improved tumor control (based on tumor genomics) with 
proton therapy would be expected to reduce health care costs for society overall. 










































































Improving planning and delivery 
In comparison to IMRT or VMAT, there are typically many more degrees of freedom for modulation in 
proton therapy, due to the 3-dimensional distribution and application of individually weighted Bragg 
peaks. These additional possibilities are only just beginning to be explored, and much can still be done 
in the treatment planning process to best exploit these possibilities to improve treatment precision and 
accuracy. On the other hand, tissue deformations can significantly affect proton ranges in the patient so 
that proton therapy is generally more affected by intra and inter-fractional anatomy changes. Reducing 
uncertainties is thus a key research theme in proton therapy physics, as is the proper quantification, 
monitoring and reporting of uncertainties. Adaptive therapy has a higher potential for clinical impact in 
proton therapy compared to conventional radiation therapy. Uncertainties also exist in the biological 
effect of proton beams. As uncertainties can never be eliminated entirely, optimization techniques are 
being developed to reduce their clinical impact. 
As these topics are currently researched heavily, there are seven roadmap contributions in this category:  
“Uncertainly precise – uncertainties in proton therapy and how to tackle them”, “Treatment planning”, 
“Development of robust planning”, "Adaptive therapy to account for daily anatomy and range 
variations”, “In vivo range verification”, “4D planning and delivery”, and “Considering the relative 
biological effectiveness of protons”. 
Improving imaging 
Modalities for pre-treatment diagnostic imaging are impacting all radiation therapy modalities. Even 
though originating in proton therapy in the 1960s and 70s, in-room imaging is currently more advanced 
in conventional radiation therapy. It is expected to make a bigger impact in proton therapy because of 
dose deposition uncertainties warranting treatment monitoring more closely but also because of dose-
shaping capabilities with proton therapy that make small corrections both necessary as well as 
achievable. Furthermore, there are various efforts to improve tissue characterization for dose calculation 
in adaptive workflows. 
There are two roadmap contributions about “Advances in imaging for proton treatment planning” and 
“Image guidance”. 
Improving patient selection 
There is an ongoing discussion about the necessity for randomized clinical trials to show a significant 
advantage in outcome when using protons in favor of photons. It is likely that for specific sites, proton 
therapy might be advantageous only for a subset of patients and model based trials to stratify patients 
into randomization have been suggested and are already being implemented at some centres. This raises 
the question about the applicability of dose-response models developed from photon treatment outcomes. 
Additionally, in the era of precision medicine, patient selection based on biomarkers is playing an ever-
increasing role. We are just starting to scratch the surface of identifying sub-populations for (proton) 
therapy based on biological/genetic fingerprints. This has to be understood also in the context of 
(systemic) treatments prescribed in addition to radiation therapy. Indeed, maybe the most important areas 
for progress in proton therapy may lie in improving our understanding of differences in biological 
responses to proton vs. photon treatments. In areas such as predicting biological response based on 
genomic features, very little is known. Many of these developments are not necessarily specific to proton 
therapy. As such roadmap contributions about “Selection of patients for proton therapy”, “Outcome 
modeling for proton therapy”, “Biomarkers in proton therapy”, and “Systemic effects of proton therapy” 
have also been included. 
Summary 








































































Research and development in proton therapy is a topic of increasing interest in radiation therapy physics, 
medicine and biology, with the number of research articles about proton therapy greatly exceeding the 
number of photon therapy related manuscripts when considering the tiny number of patients under 
treatment. How this will develop in the future is the subject of this roadmap, which collects the opinion 
of leaders in the field and their vision on how this treatment modality will advance in the near future. As 
such, there are many personal opinions contained in this article, and opinions that not all readers will 
necessarily agree with. But that of course ‘is the nature of the beast’ when different experts are asked to 
take a look into the future. In addition, in order to catch a true ‘snap shot’ of current thinking, other than 
providing broad titles to the different contributors, we deliberately avoided providing any detailed 
guidelines on content, to not restrict their creative thinking and writing. Similarly, the contributors were 
not provided access to other contributions before submitting to the roadmap collection. As such, there 
are inevitable overlaps between some contributions, which we believe only enhances the article. If a 
topic is mentioned more than once, and completely independently by different authors, does this not add 
an important, and not to be ignored, emphasis to that point?       
 
Part 1: Improving efficiency 
 
Cost reduction by optimizing Accelerator Technology 
Marco Schippers  
Introduction 
For routine clinical application of proton therapy, the cyclotron, synchrotron and synchrocyclotron will 
be the most commonly used accelerators in the near future. Although some developments are still aiming 
at a technical improvement, in general, these accelerators are considered to have reached a mature state, 
and that they have been developed sufficiently for their application in proton therapy. Therefore, in the 
coming years most improvements of these machines will be focussed on a cost reduction of the 
manufacturing and service. A reduction in size of the accelerator is regarded as a key issue in price 
reduction by the commercial suppliers of proton therapy accelerators. In parallel to these industrial 
developments, one is also working on a proton therapy application of recent accelerator developments 
in various research institutes and laboratories. After discussing the developments in synchrotrons and 
cyclotrons, these will be summarized shortly. 
Synchrotron 
Since the first phases of proton therapy, synchrotrons have been used and have been further developed 
specifically for this application. Proton-synchrotron accelerator systems are composed of a proton source 
and a linac (linear accelerator), which injects the protons into the synchrotron ring for acceleration. The 
synchrotron ring consists of several bending magnets and magnetic lenses. In the RF cavity, which is 
also mounted in the ring, an oscillating electric field is generated to accelerate the protons. The ring has 
a typical diameter of 6-8 m and the injector has a length of 6-10 m. The maximum number of protons 
that can be injected into the ring is limited (in the order of 109-1011) but this number increases with the 
injection energy. A higher filling of the ring is still an important research topic, since for the application 
of one field at the patient, one typically needs 1-3 fillings and acceleration sequences (Hiramoto et al 
2007). Therefore, a higher filling of the ring would reduce the treatment time considerably. The beam 
extraction process in a synchrotron for proton therapy, has been improved by the RF-knock-out 
technique (Hiramoto et al. 2007). With this technique the beam shape and intensity remain more constant 
during the extraction of the beam, which is of great advantage in controlling the dose application 









































































The most important cost drivers that are specific for each synchrotron type, are the ring diameter (i.e. 
the amount of magnets and their strength), the proton source, the injection system (injection Energy) and 
the RF system. Cost drivers related to the synchrotron are the footprint, systems to match the beam shape 
to the gantry angle and the ring filling and ramping time, which determine the averge dose rate at the 
patient (i.e. treatment time).  
Smaller (and thus cheaper) synchrotrons, with diameters down to 5 m have been developed in the last 
decade (Wang et al 2011, Umezawa et al 2015). Also, the footprint of several synchrotron facilities has 
been reduced by optimizing the layout of the ring, proton source and injector and by combining the 
proton source and first acceleration steps (Vretenar et al 2014). A further cost reduction has been 
achieved by reducing the number of synchrotron elements and the differences between the individual 
magnets in the system.  
A very significant improvement has been achieved in one of the synchrotrons for carbon therapy, by 
enabling a reduction of the beam energy during the beam-extraction phase (Iwata et al 2010). This is of 
optimal benefit for the necessary energy variations to cover the target in depth. This development, which 
is being implemented in some proton synchrotrons as well, can reduce treatment time by 30% in 
synchrotron facilities (Iwata et al 2010). Another development shortening the treatment time, is expected 
from an increase of the ramping speed of the synchrotron magnets (Trbojevic et al 2011). Although 
similar important improvements in facility operation are expected soon, no substantial facility size 
reductions are expected in the near future in facilities driven by a synchrotron. However, developments 
are continuing and these will optimize the synchrotron operation and yield a gradual cost reduction. 
Cyclotron and synchrocyclotron 
Since the last 25 years also cyclotrons are commercially available for proton therapy. These are single 
magnet machines, with a typical diameter of 5 m and a weight of 200 tons, which accelerate protons to 
a fixed energy. With a degrader followed by an energy selection system, all necessary lower energies 
can be obtained in a fast procedure. During the last decades important technical developments have been 
implemented into cyclotrons for proton therapy, so that several types of cyclotrons can be achieved 
nowadays. The differences in cyclotron costs are mainly related to differences in its size or mass (i.e. the 
amount of iron), superconducting (SC) coils or not, the RF system and the hardware and control of beam-
quality determining components. Other cost drivers related to the cyclotron are the energy selection 
system, shielding and activation. 
To reduce the size of a cyclotron, a stronger magnetic field is needed. This is only possible by using a 
superconducting magnet. The first SC cyclotron in proton therapy (Schillo et al 2001) has a diameter of 
3.5 m and a weight of 100 tons. Further developments have enabled even stronger magnetic fields. Very 
small so called “synchrocyclotrons” of only 30-50 tons and a diameter 1-2 m, have been produced and 
taken into clinical operation in the last decade (MEVION 2019, IBA 2019). As expected, this has led to 
a significant reduction in the price of a cyclotron. For one type of these cyclotrons, its mounting on a 
rotating gantry (MEVION 2019) has decreased the facility footprint significantly. 
However, contrary to the traditional “isochronous” cyclotrons (either with normal or with SC magnets), 
providing a continuous proton beam, the very small synchrocyclotrons can only operate in a mode with 
a pulsed proton beam. Their maximum pulse rate of 1 kHz imposes limitations on beam intensity (i.e. 
dose rate), so that one cannot have very short treatment times. Although the average beam intensity is 
limited, during the pulse the beam intensity can be quite high. At several sites this has be used for 
experiments in which small volumes have been irradiated with the very high dose rate in a pulse. Also, 
the expected very beneficial dose delivery techniques used to provide continuous pencil beam scanning, 








































































are not possible with the pulsed beams from these synchrocyclotrons. To prevent these limitations and 
to reduce the costs related to the facility footprint, several companies now offer a single-room facility 
with a compact arrangement of a gantry with an isochronous cyclotron, providing a continuous, well 
controlled beam intensity.  
In the field of SC cyclotrons, studies have also been started to design a synchrocyclotron with a magnet 
that has no iron yoke (Radovinsky 2014). This would reduce the mass of a cyclotron by a factor 10. 
However, since these ideas are still at an early design stage, no estimates on price and availability can 
be made yet.  
Other accelerator types 
Novel proton acceleration concepts based on e.g. lasers are being investigated. In laser based accelerators 
(Zeil et al 2013), major topics one is working on are: a very high beam power, a reasonable short 
repetition rate of the laser pulses, a sufficiently high proton energy and the energy spectrum of the 
protons created by the laser. 
Other developments are focussing on a beam optics concept of fixed magnetic fields and alternating 
magnetic gradients. Both in accelerators) and in some gantry designs, one is applying a beam optics 
based on strong magnetic fields of alternating polarities and gradients (Sheehy 2016 and Trbojevic et al 
2007). This has the advantage of large energy acceptance. Much effort is put in the construction of the 
tight packing of the very strong magnets of opposing polarities in a gantry design and a reduction of the 
power of such a Fixed Field Accelerator (FFA). This accelerator is based on such a beam optics of a ring 
of magnets with fixed fields having alternating strong magnetic gradiens. It is a synchroton like 
accelerator, but with fixed magnetic fields, similar as in a cyclotron. 
The first linac for proton therapy has been developed from ideas used in high-energy physics and is 
almost ready for installation at a clinical site (Degiovanni and Amaldi 2014). An important advantage of 
a linac would be the possibility for rapid energy changes for range modulation. In a linac one can simply 
switch off or change the power in one or more acceleration cavities.  
Although these developments are very important, for many of them still many steps have to be made 
before they are ready for implementation into a clinical facility. In addition to that, it is not clear yet, 
how much these developments in new acceleration techniques, will help to reduce the costs.  
Conclusions and outlook 
A brief overview of the most well known developments in accelerator technology has been presented in 
the context of a potential cost reduction of accelerators in proton therapy. Several options seem to be 
possible, but more dramatic changes are needed for a major cost reduction. And, since experience has 
shown, that major steps in proton therapy need approximately ten years from first trials to introduction 
into the clinic, it is expected that a dramatic, say 50%, cost reduction of proton therapy will not be 
reached in the near future.  
Apart from the possible lower costs, it is important to consider the effect of the new techniques on the 
treatment possibilities. For each new technology, it should be verified whether the dose distribution 
delivered provides comparable quality to that currently available in proton therapy. Compromises taken 
to reduce the cost should not be accepted when this cannot be guaranteed. For the time being, the higher 
quality of the proton treatments is the only important reason to be competitive to other treatments. 
Accelerator related properties like intensity, pencil-beam size, energy spectrum, stability, 
reproducibility, time structure and the time needed to change a parameter, are the most relevant to 
consider in this respect. 










































































Nevertheless, already now many successful developments in accelerator technology are available in 
commercially available facilities. Some of these are focusing on the lower initial investments when 
acquiring a proton therapy facility with only one treatment room. Single-room facilities will offer 
opportunities in certain cases, but it is not clear in general, whether single-room facilities will make with 
proton therapy treatments cheaper.  
At present it is encouraging to see, that accelerator developments, such as smaller accelerators, facility 
size reduction and faster treatments, are entering into clinical facilities and are contributing to a reduction 
of the treatment costs. Next steps in cost reduction can only be achieved with further research in 
accelerator physics.  
 
Technology for delivery efficiency 
Jacob Flanz 
Introduction 
The spatial distribution of a beam from a particle accelerator is not normally a conformal match for the 
desired target. Therefore, one must direct the beam trajectory and ‘spread out’ the beam transversely and 
longitudinally (in depth). In doing so, one attempts to optimize the 3 dimensional distribution and in 
some cases a 4 dimensional distribution, the latter including the time dependence of beam delivery 
relative to patient motion (see article on “4D planning and delivery”). A key goal is to deliver a physical 
dose distribution consistent with a predetermined treatment plan. This treatment plan includes specifying 
the direction that this spread out beam should enter the patient. 
For decades the main delivery modality was that of beam scattering (Koehler et al 1977). This is 
accomplished by scattering the beam with various types of physical devices in the path of the beam. 
Sometimes this is done passively enabling the entire volume of the dose to be delivered instantaneously 
and in some cases it has more dynamic elements such has range modulator wheels and beam current 
modulation, which can deliver the full volumetric dose in a fraction of a second. The beam delivery 
modality which has evolved to be the more desired and soon-to-be the most prevalent is that of beam 
scanning (Pedroni et al 1995) wherein the unmodified accelerator beam distribution is transversely 
scanned magnetically and the beam range is controlled by modifying the beam energy both of which 
have a finite time dependence. This beam was originally delivered from a fixed angle beamline, but then 
proton and heavy ion gantries were developed.  These added needed (at the time) flexibility in beam 
direction as well as considerable expense. 
For the purposes of this section, the word “efficiency” is interpreted to mean efficient in cost, time and 
treatment efficacy. 
Status 
Most of the modern facilities are designed to use particle beam scanning with rotating gantries. Most 
have been constructed to deliver a dose rate of about 2Gy per liter in a minute.  Scanning beams hold the 
promise to deliver the most conformal physical dose distribution, however the ultimate dose distribution 
possible according to the laws of physics is still not achieved as a result of certain constraints and 
limitations. Recently, different beam delivery methods are being re-explored, such as mini-beam ribbon 
(Peucelle et al 2015) and FLASH (Mazal et al 2020) (see article on “Treatment planning”) irradiation. 
These modalities may require revised beam delivery parameters including much higher dose rates. 
Current and Future Challenges 









































































This chapter focuses on the system components used to direct the beam to the patient including the beam 
spreading technology and the gantry. The challenges to be addressed here are specific to these 
components. Elsewhere, issues of localization and stopping power uncertainties will be addressed.  
Given the current beam delivery implementations, the necessity to address organ motion results in 
applying methods that include: Gating, Repainting and Beam size adjustment. The current systems are 
capable of these techniques. However, their design may be constrained to avoid the fundamental issues 
that would address the key challenges of the future.  These challenges include: 
• Reduced system cost, and 
• Faster, accurate and safe beam delivery 
The beam scanning delivery technology involves informing the system of the desired location and dose 
to be delivered in real time. If one knew precisely where the target was at any given time, the equipment 
technology is capable of producing and delivering a beam to that location. However, treatment planning 
has not yet reached the capability to calculate and transfer real time adaptive plans based upon the dose 
delivered with real time imaging (see articles on “Treatment planning”, “4D planning and delivery” and 
“Adaptive Therapy”). Therefore, one would first consider pre-planned delivery options. 
Delivering a 3D dose distribution in a time period small compared to organ motion would be a 
fundamental solution to handle the organ motion challenge. Currently, on the average, it takes on the 
order of a minute to deliver the volumetric dose required by the treatment plan (see article on “Delivery 
Technology”). This is comprised of two seconds or less to change the beam energy, each time it is 
required, and the time to paint a given range layer which is about, on the average, a second. Therefore, 
30 layers will take about a minute.  Some facilities are capable of faster delivery, such as 0.1 seconds to 
change energy. However even that amounts to more than 3 seconds total for just the energy changes, not 
short compared to the period of organ motion (respiratory or cardiac). Scanning dipoles exist with the 
capability of moving the beam at frequencies of 100 Hz (although the slowest ones move at 3Hz), and 
for spot scanning the settling time of the magnet/power supply combination can be as large as 5msec per 
spot (which, for 40x40 spots, could result in a ‘dead-time’ of about 8 seconds per layer). Furthermore, 
FLASH beam delivery requires dose rates of >40 Gy/second. It’s not exactly clear what the beam 
delivery implications will be for this technique. Is that dose rate in the distal layer only sufficient, or is 
it required for the full volume and is there a time dependence, as in painting the volume, to the effect? 
Another aspect of this challenge of increasing the speed of the beam delivery are the commensurate 
issues of accuracy and safety in delivering the beam. One expects a dose delivery accuracy of better than 
2%. Currently Ionization chambers (IC) are predominately used (in fact they are legally required in most 
countries).  These systems may take 100usec, on the average, to detect and record the dose delivered. 
Therefore, there is always a delay and it is essential that the dose rate is such that the dose tolerance 
should not be exceeded in the time it takes to detect it. This results in a limitation of the beam current to 
fractions of a nano Ampere and results in dose rates that are currently used. To increase the speed of the 
scan or beam delivery current a factor of 60-100, to address organ motion, or a lot more (for FLASH) 
would require advances in the technology. The challenges identified so far include: 
• Speed of Scan 
• Speed of Ionization Chambers (ICs) 
• Speed of Energy Change 
When considering the cost of a particle therapy facility one cannot compromise on safety.  One desires 
to deliver the beam to the appropriate target location in a speed consistent with the target accuracy 
desired. One of the most expensive pieces of equipment in a particle facility is a gantry. The size, weight, 
fabrication and building structure for such a piece of equipment is probably the single largest expense in 









































































the facility. Attempts to reduce the cost of this component include shrinking its size longitudinally (via 
superconducting magnets (Gerbershagen et al 2016) or corkscrew geometry (Koehler 1987), or reducing 
the lateral extent by limiting the rotation range to about 180 deg (Pedroni et al 2004). However, while 
the superconducting option can reduce the cost of these systems for heavier Ion facilities, it does not 
reduce the facility size significantly for proton centers. The largest cost reduction would come from the 
elimination of the gantry mechanical component. 
Advances needed to meet the challenges 
If one looks again at the key challenges, perhaps one can identify the most appropriate way to address 
them, given what is known now or can be imagined now.    
Speed of Scan: Conventional magnets exist that can move the beam quite rapidly.  The issue is how big 
they need to be, which is related to the size of the field extent and the distance from the magnets to the 
target.  Without a gantry (solving two problems with one solution) the distance can potentially be larger 
and the magnets smaller, with lower inductance enabling reduced dead time and faster current changes.  
However the dose rate must be sufficient to deposit the desired dose in the time, and while most 
accelerators can do this, the existing ICs used cannot.   
Speed of Ionization Chambers: Smaller gap, higher voltage systems are required, which may be possible 
since the scanning beam modality requires lower beam current than was necessary in the scattering 
systems.  Or perhaps one can replace these with alternative options. For example, knowledge of the 
beam’s incoming trajectory together with the magnetic field should be capable of accurately predicting 
the position of the beam on target, thereby avoiding the need for additional redundant instruments such 
as Ionization chambers.  Other instruments for counting charge such as toroids or scintillators might be 
considered to replace ionization chamber dose monitors. This may necessitate modification of the 
regulations. 
Speed of Energy Change: This is perhaps the most technologically difficult issue. The contributions to 
this time include the accelerator (for some systems) and the beam line. Synchrotrons are now starting to 
use ‘multi-energy’ extraction (Younkin et al 2018), and cyclotrons rely on a degrader with the magnetic 
energy analysis system.  One method is to eliminate a beam line (Prusator et al 2017), which is possible 
for a single room system.  Otherwise the magnetic beam line system must be designed to enable faster 
energy changes (e.g. on the order of 0.02 seconds).  This is possible from an engineering point of view, 
but may increase the system costs and commissioning complexity. Feedback and feed-forward systems 
are possible, some examples of which have been implemented.  
System Cost: The simple, and yet not widely accepted answer is to eliminate the gantry.  With decades 
of experience using gantries, given the convenience of setting the beam trajectory and patient 
positioning, it is hard to conceive of this disruptive change.  Prior to gantries one used fixed beam lines 
for treatment and experienced difficulty in achieving the desired beam angles relative to the patient 
orientation.  However, one needs to consider the modern systems, with scanning beams, robotic 
positioners, more flexible imaging and flexible immobilization.  Scanning beams are highly conformal, 
and that means that they are capable of delivering a conformal dose with fewer and more limited field 
angles.  Studies have shown that fewer non-coplanar field geometries are necessary (Yan et al 2016).  
The issue is then what is the range of patient orientations that are necessary and how to ensure that the 
patient anatomy is in the appropriate position for these geometries?  Robotic positioners can orient the 
patient in flexible positions (upright, lying down and forms of sitting) and in-room imaging is capable 
of verifying a patient’s position in multiple orientations, if that is needed in the course of one fraction 
(e.g. orientable CTs, swing arm CBCTs). Comfortable and easy to use immobilization is perhaps the 
element most lagging in this equation. Developments of this are underway. 










































































The evolution of beam delivery technology is sometimes done adiabatically. While the change from 
scattering to scanning was, in fact, a disruptive technology, the former has slowed the evolution of the 
latter.  Sometimes one has to identify the issues very clearly and boil them down to their essence to, in 
this case, realize that one needs to use an appropriate imaging technology and immobilization to enable 
a gantry-less solution and deliver a beam very quickly.  These are the technologies that will deliver the 
largest gain. Probably the most important development to achieve these goals is improved beam 
instrumentation, or a revisiting of the type of instrumentation that is required.  Perhaps it may be noted 
that there is another goal relevant to beam delivery technology, which at first thought may appear 
separate from the considerations identified above, but upon further reflection may become the magic 
bullet of radiotherapy. If this “FLASH” radiotherapy turns out to be shown to be favorable in humans, 
then the imperative to address the fast dose delivery with charged particle imaging will enable further 
significant reduction of side effects to healthy tissue while enabling delivery of the dose in a time scale 
short compared to motion and delivered to the correct location and depth as given by direct charged 
particle imaging. It is critical to direct the evolution of the technology to address the current challenges 
and finally achieve what charged particle therapy has ultimately promised for the past half century.  And 





One of the areas where a significant cost reduction in Proton Therapy (PT) seems possible and achievable 
is in the potential of increased efficiency (see article on “Efficient Treatment Room Utilization”). As 
today, the allotted treatment times are typically significantly longer in PT than in conventional, linac-
based treatments (Suzuki et al 2016).  
There are many reasons for the longer treatment times in PT, e.g. on average more complicated 
treatments with several fields with/without the use of range shifter, a higher need for imaging due to the 
need for rapid adaption and the sharing of the accelerator with several treatment rooms. Despite the 
increasing installations of “single room” solutions in recent years, multi-room facilities with anything 
from two to five rooms still dominate. Sharing the beam means that one or two (or even three) rooms 
may be before you in line when you are ready to treat. A slow field delivery time hence also affects all 
those rooms waiting for the beam and any second gained by faster beam delivery will be multiplied by 
the number of rooms waiting. Waiting time may also deteriorate the treatment since the patient may 
move during this period and call for additional imaging or position verification. The cost for a treatment, 
or fraction, scales more or less linearly with the time the patient spends in the treatment room and 
reducing the length of the time slot, without compromising the quality of the treatment, will consequently 
reduce the cost to the same extent. 
Advances in Technology to meet challenges 
Looking deeper into the technological solutions for spot scanning facilities today, one easily gets the 
impression that the concept of treatment efficiency has largely been neglected in the design process. The 
different accelerator types (cyclotrons, synchrotrons and synchrocyclotrons (see article on “Accelerator 
Technology”) all have different characteristics and will therefore in the following be partly treated 
separately, although the main focus will be on (isochronous) cyclotrons, since it is the most used type of 
accelerator in PT. 










































































There are three main parameter ruling the time it takes to deliver a given treatment field; the spot 
delivering time, the time between spots and the time it takes to change the energy (see article on 
“Technology for delivery efficiency”). A cyclotron produces a continuous beam (ignoring the RF 
frequency pulses) and to deliver a spot with a given number of protons (or MU´s), the beam is turned 
on, the dose is monitored by a dose monitor and turned off when the pre-set value is approached. This 
means that the signal from the monitor chamber must be tracked and analysed in real-time and to achieve 
a high degree of accuracy, a certain time, typically a few ms, is needed. Prior to irradiation, an estimate 
of the needed beam current is done by the system to ensure the spot duration not being too short. With 
faster electronics and analytical capacity, this could probably be somewhat reduced in the future. 
However, and more importantly, the possibility to adjust the beam current from the accelerator between 
consecutive spots is of crucial importance. In some systems this can be done, meaning that all spots have 
(more or less) the same duration of a few ms, whereas in other systems, the beam current is calculated 
to ensure that the smallest spot (with the smallest number of MU’s) will be long enough, and the 
modulation of the spot intensity over each energy layer, is done by prolonging the spot duration with the 
same beam current. In the latter case, the time to deliver a field will typically be at least twice as long, 
as if the beam current was modulated (Müller and Wilkens 2016). The actual prolongation depends on 
the amount of modulation the spots in the field have and on the minimum number of MU’s allowed, but 
it’s important to realize that even in single field optimized treatments, there is a significant spot 
modulation, also within each energy layer.  
In a synchrotron, the situation is similar in this respect. The accelerator is loaded with a certain number 
of protons and then the protons are extracted in “spills” and the accelerator is filled up again. During a 
spill, the beam can be viewed as continuous and the same principles as for a cyclotron can be applied.  
A synchrocyclotron represents a completely different situation. Here the beam is pulsed with a beam 
duration of only a few µs per pulse, pretty much like in a linac. Hence, the pulse duration itself does not 
really contribute to the beam delivery time, but since the number of protons (or MU’s) delivered in a 
pulse is ruled by the upfront loading of the cyclotron, rather than by the reading of the monitor chamber, 
more than one pulse is needed to build up a spot. This is due to the fact that the number of protons in a 
pulse cannot be predicted (or determined) at the ion source level to the accuracy needed in PT. The 
important factor that rules the actual beam delivery efficiency then becomes the pulse repetition 
frequency (PRF), which scales more or less linearly with the efficiency. For the present and most widely 
spread synchrocyclotrons, the PRF is between 500 – 1000 Hz; increasing the PRF will directly reduce 
the beam delivery time.  
The second parameter determining the beam delivery time is the time between spots; the time it takes to 
move from one spot position to the next. This is mainly governed by the speed of the scanning magnets. 
When the magnetic field is to be changed in an electromagnet, eddy currents generated in the yoke of 
the magnet reduces the speed of which this change can be done. A way to counteract this effect is just to 
wait until the magnetic field has settled and stabilized. If this time is to be reduced, an approach could 
be to predict the spot position effect due to this and compensate for that, and in that way allow a reduced 
settling time (Psoroulas et al 2018). Another method is to introduce “line-scanning”. With this approach 
the pencil beam is continuously moved in lines over the area to cover. Modulation of the beam intensity 
can either be made by modulating the beam current, or by keeping the current constant but modulating 
the speed of the scanning magnets, or both (Klimpki et al 2017). A prerequisite is that the beam current 
is stable enough and this may present a challenge for synchrotron-based systems. This method can be 
made significantly faster and solves, at least to some extent, both the problem of spot duration and the 
dead time between spots, but is demanding in terms of beam delivery monitoring and validation. To 
perform line scanning, a continuous, rather than pulsed beam, is needed. Hence, line scanning cannot be 









































































performed with a synchrocyclotron. 
The third parameter is the time it takes to change the energy from one layer of spots to the next. For most 
modern cyclotron based systems, this time is around one second, or slightly more. Large efforts have 
been done to reduce this at some centres, e.g. at the Paul Scherrer Institute in Switzerland (Klimpki et al 
2018). The main purpose of this is to better manage organ motion and e.g. to make volumetric re-painting 
feasible, but without doubt, this parameter also influences the overall efficiency.  
In synchrotrons, each energy layer typically demands a spill of its own. This means that even if the 
number of spots within a certain energy layer is small, the accelerator has to go through the whole 
acceleration cycle, which takes typically several seconds. For details of the timing of synchrotrons in a 
clinical context, see e.g. (Gelover et al 2019; Boria et al 2018). Ways to improve this has been done by 
e.g. by decelerating the beam during a spill (Iwata et al 2010; Younkin et al 2018) and with the so-called 
multiple energy extraction method, beam delivery time can be reduced by a third for typical clinical 
fields. Another approach to speed this up can be to decrease the “dead time” between the spills by 
increasing the ramping speed of the magnets (Trbojevic et al 2011).  
Once a PT system is installed, most of the above parameters are given and cannot (easily) be improved 
or changed. If the time to deliver a spot and to move to the next position cannot be changed, the actual 
number of spots in a given energy layer can (van de Water et al 2019). Larger spots mean that larger 
distance between spots can be applied, and hence fewer spots can be used without causing a dose ripple 
(for further relevance of this, see also article on “Treatment planning for pencil beam scanning proton 
therapy”). Fewer spots with a larger number of protons in each spot, is associated with significantly 
reduced beam delivery time. The exact reduction is dependent on several parameters such as available 
beam current and is also different between different delivery systems. Several PT vendors offer different 
“spot ID’s” by the introduction of a scattering foil in the treatment head (nozzle). The price to pay for 
larger spots is a larger penumbra and somewhat reduced modulation possibilities and consequently this 
approach has not become a standard tool in most clinics. A way to overcome this would be to allow 
different spot sizes within the same energy layer, e.g. smaller spots at the edges and larger spots in the 
central part of the field. To make this possible, rapid changes of the spot sizes are needed which is 
difficult with a scattering foil. With present systems the foil is either in or out during the complete field. 
Attempts to widen the beam with magnetic defocussing instead of a scattering foil have been explored 
but is not widely available. However, such an approach would also have the appealing quality of 
designing the actual spot size individually for each energy, which cannot be done with a limited number 
of scattering foils. Yet another approach to solve the penumbra drawbacks of larger spots is to combine 
the scanning with a collimator. Advanced solutions are required in order not to detract the other obvious 
advantages with the spot scanning technology. One such commercially available solution is the so-called 
Hyperscan from Mevion (Kang et al 2018). 
The equivalent of spot size in the depth direction is the initial energy spread of the proton beam. Typically 
this is around 1 %, resulting in a very steep distal fall off of the Bragg peak. Although this is often seen 
as an advantage with PT, the sharpness of the peak may be too sharp, in particular at the low energies, 
to be clinically useful (considering e.g. range uncertainties) and results in very small energy steps and 
many energy layers to avoid a dose ripple. One way to intentionally introduce an increased energy spread 
and hence soften the Bragg peak is to apply a ridge (or ripple) filter (Printz Ringbæk et al 2017; Grevillot 
et al 2015). With a proper design, virtually any shape of the Bragg peak can be obtained. But just as with 
scattering foils to broadening the spots, a ripple filter is yet another mechanical device to be introduced 
into the beam line, typically by manual handling, with limited possibilities to change between energy 
layer or, even more so, from one spot to another. If the gantries could be designed with a wider 
momentum spread acceptance, the energy spread could be determined further up-stream in the beam line 









































































and in cyclotrons there are already a momentum slit in the energy selection system that could be used 
for this purpose (Hsi et al 2009; Nesteruk et al 2019). But again, the actual acceptance of the beam line 
is given by the original optical design and cannot (easily) be retro changed. The longer it takes to change 
the energy of the proton beam, the more important it gets to optimize the number of energy layers used. 
This aspect can be introduced in the treatment planning optimizer and significant energy efficiency gains 
have been demonstrated (Kang et al 2008; Cao et al 2014; van de Water et al 2015). An exception to the 
above situation is the gantry-mounted design by Mevion where no energy selection is present and the 
sharpness (or lack thereof) is the same independently of energy. 
In conventional radiotherapy, the move from IMRT to volumetric modulated arc therapy (VMAT), led 
to a significant efficiency gain. A similar development has been demonstrated also for PT (Li et al 2019), 
but since the difference in dose distributions are greater than in the photon case, it is probably too early 
to know if proton arc therapy will become a standard delivery tool in the future. In IMRT a relatively 
large number of fields are typically used, meaning that the dose is distributed to larger volumes. This 
effect is even larger in VMAT, yet smaller than the difference is between IMPT (where relatively few 
fields are used) and PT arc therapy. 
This far the beam delivery time has been discussed. Obviously the beam-on time is just a small part of 
the overall “patient-in-the-room” time and an increased “Dose rate” may only have a limited effect on 
the overall efficiency. But for many of the systems a reduction by a factor of two or more for the beam 
delivery time seems realistic and for multi room systems, this could result in an improved efficiency of 
the order of 10 – 25%. If complex beam delivery applications are used, e.g. re-painting or gating for 
motion mitigation, the efficiency gain is even higher. 
As mentioned above, a faster beam delivery time will have the greatest impact on multi room facilities, 
where the waiting time for the beam is an obvious limitation (see article on “Efficient Treatment Room 
Utilization”). But also the beam sharing system itself is of importance. Most systems have the possibility 
to choose a “priority” for their treatment, i.e. to choose whether or not to give the beam away between 
consecutive fields of a patient. To accept to give the beam away reduces the waiting period each time, 
but increases the number of room switches and increases the overall treatment time. Faster room 
switching, e.g. by allowing dedicated power-supplies to each gantry-specific magnetic component, rather 
than sharing those, and smarter scheduling tools, might reduce the problem. Future design improvements 
with the possibility to share the beam, i.e. deliver beam to more than one room at the time, may be 
possible, but this is technically complicated and will lead to increased equipment costs (Schippers and 
Lomax 2011).  
Image guidance (IG) (see article on “Image guidance”) is used extensively in PT and this obviously 
slows down the efficiency. One cannot argue for reduced IG as long as it improves the quality of the 
treatment leading to improved clinical outcome. However, IG in PT is often to a substantial part also 
used as a technical quality control to make sure the equipment, in particular the robotic patient positioner, 
is in the right position, rather than checking the positioning of the patient or the target. Poor accuracy 
and precision of the patient couches is still a problem and limited trust in the equipment leads to over-
imaging and prolonged treatment sessions. 
Manual handling of beam modifying devices, in particular range shifters constitutes a substantial source 
of inefficiency, in particular for installations where the range shifter cannot be remotely operated. To 
counteract this source of treatment prolongation, it is not uncommon with a sub-optimal use of the range 
shifter, e.g. to use it for all fields, even those where it’s not needed, just to avoid the delay of manual 
handling, but with a deterioration of quality. Improved penumbra and better dose distributions can 
sometimes be achieved by splitting the fields and use the range shifter only for the energy layers it’s 
really needed, but to apply this method in an efficient way, automation is needed (Francchiolla et al 









































































2017). Remotely operated range shifters are urgently called for and it should not be an unsolvable issue 
also for existing clinics. 
As discussed in a previous chapter (see article on “Technology for delivery efficiency”), gantries in PT 
constitutes a significant part of the investment. The gantries in PT are substantially larger and heavier 
than conventional gantries. As a consequence and for safety reasons the gantry speed is sometimes 
limited compared to the 1 RPM commonly encountered in conventional radiotherapy. Some systems 
also experience a “cork screw effect”, meaning that the exact position of the gantry is depending on the 
direction from which the position is approached, i.e. clockwise or counter-clockwise. For some systems 
an “over-travel” is needed if the gantry is rotated from the wrong direction, meaning a further 
prolongation of the treatment session. The issue of heavy gantries may not be trivial to fix for existing 
gantries, but should be a parameter to consider when procuring a PT system. The over-travel issue, 
however, is expected to be solvable. 
Concluding remarks 
There are a number of reasons why PT is so much slower than conventional radiotherapy. To a significant 
degree this could be improved in future designs by ensuring a faster beam delivery time, faster and more 
reliable gantry designs and maybe even by the possibility to share the beam in a smarter way in multi 
room facilities. For existing facilities, the options are limited when it comes to the beam delivery 
technology, but there are some obvious issues that should be promoted, e.g. remotely controlled range 
shifters, the possibility to modulate the beam current in-between consecutive spots and multiple energy 
extraction for synchrotrons.  
 
Efficient Treatment Room Utilization  
Chris Beltran and Keith Furutani 
Status 
Efficient utilization the Particle Treatment room for patient treatments and quality assurance will reduce 
the overall cost of treatments and improve patient care. The overall financial impact of a facility is not 
only the upfront equipment and building expense, but in the long run it will be efficiency of daily patient 
treatment and room occupancy that dictates true cost of operation and patient treatment cost.  In this 
section, we will assume sufficient demand to fully occupy a given facility; therefore, details and method 
of effective demand generation will not be discussed here but is a crucial concept in cost reduction.    
There are four main time components for patient occupancy in the treatment room: 1) patient and 
therapist entering and exiting the treatment room; 2) immobilization and image guided localization; 3) 
beam on time; 4) equipment preparation (gantry and table rotations and beamline settings).  The other 
major room occupancy is the quality assurance (QA) procedures that must be conducted.  This includes 
daily, monthly, annual machine QA and patient specific QA (PSQA).   
The current status for room patient room occupancy is as follows: 1) 4-5 minutes to enter and 4-5 minutes 
to exit the treatment room; 2) 4-5 minutes for immobilization and 3-5 minutes for image guidance; 3) 2-
3 minutes of beam on time; 4) 3-6 minutes for gantry rotation and beamline settings.  This gives a total 
of approximately 20-30 minutes, which is currently difficult to achieve in most centers.  These are just 
approximations, as some treatment sites may take longer.  Many current proton facilities reserve 20 to 
45 minute time slots for the average patient, while most photon facilities reserve only 15 minute time 
slots, this incudes facilities with have both proton and photon capabilities. 
Current and Future Challenges 








































































Current challenges include the fact that particle therapy is particularly sensitive to small anatomical 
changes, which can erode the quality of the target coverage and normal tissue sparing (see article on 
“Uncertainties”). This makes the immobilization and image guidance step extremely crucial (see article 
on “Image guidance”). A lot of time is spent in the image guidance step, as the data provided is not 
always fully informative as to the acceptability of the current patient setup. For example, if the image 
guidance currently shows partial sinus filing in a head and neck plan that had none during simulation, 
what is the compromise, if any, to the target coverage and/or normal tissue sparing?  These types of 
changes are difficult, if not impossible, to account for with robust optimization planning techniques. 
In the future, many treatment sites will move toward hypo-fractionation and/or incorporating some type 
of target motion mitigation technique to reduce the interplay effect (under or over dosing due to beam 
scanning motion relative to breathing motion). As these trends continue, the limitation in effective dose 
rate will become more pronounced. The current dose rate standard is approximately 1 to 2 Gy/min to a 
cubic target with a one liter volume; however, this dose rate is difficult to achieve with real targets. This 
limitation is mainly due to energy layer switching time, spot scanning time, and effective particle current 
at lower energies. For multi-room facilities is the additional limitation due to a finite field or course or 
room switching time. A typical room switching time is 20-45 seconds, given 120 fields a day and 30 
seconds switching time this is an hour per treatment room that is “wasted”. 
The increase in hypo-fractionation will also increase the number of PSQA as the expectation will be to 
treat more patients in a given month and hence increase the PSQA workload. The current practice for 
PSQA in many centers is time consuming and with no change in efficiency will limit the total number 
of new patient starts in a given month. 
Advances in Technology to meet Challenges  
Many centers are beginning to adopt a log based/machine files approach to PSQA (Johnson et al 2019 
and Belosi et al 2017). This is a first step to decreasing the amount of time the treatment room is utilized 
for PSQA and thereby freeing up more time for patient treatments.  Specifically, a log based QA 
approach uses the data from the treatment delivery system to ensure proper delivery of the radiation. The 
cited references detail how this is done and quantifies the time savings. Another practice currently being 
implemented in some clinics is the use of direct shield doors. These doors open quickly and eliminate 
the need for a long maze; thereby reducing the time needed for patients and therapist to enter and exit 
the treatment room. While implementing advanced IGRT such as high quality CBCT is crucial, the 
particle gantry rotation speed remains an issue.  Work is currently being done to increase the gantry 
rotation speed to from ½ rotations per minute (RPM) to 1 RPM. Other proposals suggest a closed design 
such that the 1 RPM restriction will no longer be an issue issue (similar to a TomoTherapy design).  
Research and development is also underway to improve the effective clinical dose rate.  This will not 
only reduce treatment time, but may allow for minimization of the interplay effect. The goal is to allow 
a stereotactic field of ~200 cc to be delivered within one small breath-hold, ~5 seconds. Accelerators 
such as the VEMIC (Hori et al 2019) would allow high dose rates at all energies without the use of an 
energy degrading device. The time required for beamline settings, particularly in a multi-treatment room 
with one accelerator setup is being addressed twofold: first by having one accelerator support only one 
treatment room, and two by optimizing the time required to reset the beamline from room to room for 
multi-room systems. 
In addition to the mechanical and control system improvements described above, much advancement is 
needed in the treatment planning realm.  One method the treatment planning can aid in treatment room 
utilization is by optimizing the spot pattern to reduce the overall treatment delivery  (see also articles on 
“Delivery Technology” and “Treatment planning”). However, the key improvement will be the 
realization of Real-Time Adaptive Therapy, which will require Real-Time PSQA that does not need to 









































































occupy any treatment room time and is transparent to the end user. Particle therapy is, in general, more 
sensitive to setup and anatomical differences than is photon therapy (see article on “Uncertainties”). This 
sensitivity increases the time used during setup and image guidance. The use of efficient Real-Time 
Adaptive Therapy (see article on “Adaptive Therapy”) can lead to decreased room time and increased 
dosimetric plan quality.  
Concluding Remarks 
As we can see from the previous section, there is no reason that in the near future we cannot have efficient 
treatment room utilization for both patient treatments and QA that will enable the cost of therapy to 
decrease while simultaneously increasing the quality and effectiveness of the delivered treatments. These 
advancements in technology are either currently being implemented in select clinics or are on the 
roadmaps of different vendors and/or facilities. The relative weight of each item to the efficiency gains 
is hard to assess as it depends on the details of the individual system, but these are items to consider and 
do a thorough investigation on when designing a future system. With these advancements, there is no 
reason that a patient time slot cannot be 15 minutes or less, similar to most current photon treatments. 
 
Part 2: Improving planning and delivery 
 
Uncertainly precise – uncertainties in proton therapy and how to tackle them 
Tony Lomax 
Introduction 
Uncertainties are an inherent part of the radiotherapy process, but have been particularly highlighted in 
proton therapy. Indeed, there is hardly a conference or workshop in this field where ‘robustness’ (the 
corollary of uncertainty), in the form of tools for its evaluation or optimisation, is not a hotly discussed 
topic. In many ways, this is a very healthy development. On the other hand, are we in the community 
really putting our resources in understanding the most clinically relevant uncertainties? In this brief 
article, we will identify fourteen sources of uncertainties in the whole process of proton therapy, each 
one identified by a roman numeral. Based on this, we will propose a list of uncertainty issues that should 
be addressed in particle therapy in the next years, together with an estimate of their relative clinical 
relevance. These are summarized in table 1. Note, that the categorization and estimates of clinical 
relevance in the table, and indeed throughout this short article, are necessarily based on a very personal 
view which some may find controversial. As such, the author does not expect that all readers agree with 
the views expressed here. But I do hope that the sometimes provocative statements promote some debate. 
Current and future challenges 
Clinical uncertainties: Uncertainty raises its ugly head already at the time of diagnosis (or the missed 
diagnosis) of cancer (I). But even once a tumor is identified, it cannot always be stated with certainty 
what the histology of the tumor is, or even more, its stage of advancement and spread (II). Nevertheless, 
all these factors will have a substantial impact on the management of the disease, which from the point 
of view of radiotherapy means the definition of the total doses and fractionation scheme with which the 
tumor should be treated, as well as the size and form of the expected microscopic spread of the disease. 
Indeed, this delineation step has been well documented to be haunted by huge uncertainties and inter-
clinician variability (Mercieca et al 2020, Apolle et al 2019, Aznar et al 2017) with the contours for the 
same patient varying by typically 3cm (Hausdorf distances) for some indications (III).      









































































Biological uncertainties: At the most fundamental level, the above-mentioned clinical uncertainties are 
related to the underlying biology of the patient, their normal tissues and the tumor. In addition however, 
there are substantial uncertainties in the biological response to radiation of the patient and tumor (see 
article on “Biomarkers”).  
Perhaps, and as discussed in an accompanying roadmap  article on the relative biological effectiveness 
(RBE) in this issue, the largest biological uncertainty is due to the inherent variation in individual 
sensitivity of patients to radiation (IV). In addition, there is considerable uncertainty in dose response at 
the cellular level, as typically characterized by the Linear-quadratic model. For this, tissue specific alpha-
beta values are notoriously difficult to determine in vivo, and even the model itself is likely a gross 
simplification of the complex mechanisms of radiation damage at the cellular and organ scale (V) (Unkel 
et al 2016, Nagle et al 2018). Finally, and perhaps the most clinically relevant biological uncertainties, 
is our current lack of knowledge of the clinical response of tumors and organs to inhomogeneous dose 
distributions (VI).  
All of the above are common to all forms of radiation therapy. For particles however, there is the 
additional uncertainty of their differential biological effect, typically characterized as an RBE. The 
variability of this is covered elsewhere in this issue, but in addition, there is mounting evidence that the 
fundamental differences of DNA damage by particles will lead to effects more complex than can be 
encapsulated in a simple relative value (VII) (Grosse et al 2014). Much still needs to be understood in 
this respect that could substantially affect how particles will be exploited in the future.         
Positioning and anatomical uncertainties: Positioning and anatomical uncertainties are present for both 
photon and proton treatments. However, particularly for anatomical changes, proton treatments are 
significantly more sensitive to such changes than in conventional therapy. For instance, in addition to 
potentially deforming the tumour and surrounding normal tissues, more importantly for proton therapy, 
they can significantly affect particle range in the patient. Indeed, for many anatomical regions, 
uncertainties in the accuracy and precision of proton treatments resulting from time dependent changes 
of the patient themselves can be huge, and substantially larger than many other uncertainties (see e.g. 
Albertini et al 2008, Hoffmann et al 2017 and Nenoff et al 2020).  
Such changes can occur either between (inter) or within (intra) fractions. For some inter-fractional 
anatomical changes, for example variable filling of internal cavities, weight loss/gain or tumor 
shrinkage/growth, substantial changes to target coverage can result (VIII) (Albertini et al 2008, 
Hoffmann et al 2017). Intra-fraction motion adds to this uncertainty cocktail, with both cyclical motions 
(e.g. breathing, heart beats etc.) (IX) (Grassberger et al 2013), as well as slower time-scale drifts of the 
patient anatomy and/or tumor (base-line shifts) (X) adding considerable uncertainty to the treatment (see 
article on “4D planning and delivery”). 
Delivery uncertainty will also occur due to the inevitable inaccuracy with which a patient can be 
positioned in relation to the treatment beam on a day-to-day basis (XI). This is a well documented 
problem, with many proposed solutions already available, ranging from the use of the statistically 
calculated planning target volume concept, through to plan optimization that also incorporates multiple 
set-up uncertainty scenarios (Unkelbach et al 2018).  
Imaging uncertainties: Even without anatomical and set-up variations, there will always be an inevitable 
‘base-line’ of uncertainty of the range of particles in the patient, simply due to the indirect imaging 
processes currently used for estimating in vivo range (XII) (see article on “Imaging for treatment 
planning”). For example, single-energy X-ray CT has been predominantly used for calculating proton 
range in the patient. In the community, such an approach is estimated to have an uncertainty of +/-3-
3.5% (Paganetti 2012), although this will be lower in most soft-tissues, whilst being somewhat higher in 








































































some forms of hard bone. The introduction of dual-energy CT has now decreased this to about the +/-
2% level (Wohlfahrt and Richter 2020). In the presence of non-biological implants such as metal teeth 
fillings and surgical stabilizations however, range uncertainties can be locally much larger, due to 
artifacts resulting from limitations in the image reconstruction processes when high-density materials 
are present.   
Dose calculation uncertainties: Despite having sophisticated tools for designing, simulating and 
evaluating treatments either before (in the treatment planning process) or after (for outcomes analysis) 
treatment, the accuracy with which such systems can predict the point-to-point dose within the patient 
are limited, even if all the other patient related uncertainties are ignored (XIII). Although MC 
calculations are undoubtedly more accurate than analytical approaches, and will become increasingly 
useful as calculation times reduce (Qin et al 2016, Schiavi et al 2017, Ma et al 2018), their accuracy is 
ultimately limited by how well the patient anatomy is represented by the CT on which dose is calculated 
(c.f. Positioning and Anatomical Uncertainties above).  
Machine delivery uncertainties: The final category of uncertainties considered here are those of the 
delivery machine (XIV). Briefly put, uncertainties in machine delivery are negligible in relation to the 
other uncertainties affecting fractionated particle therapy, at least if monitored and pro-actively corrected 
as part of a comprehensive quality assurance program. Nevertheless, there are undoubtedly areas for 
improvements in machine design and technology that can help to reduce patient related uncertainties, 
such as improved on-board imaging to help mitigate inter-fractional patient changes, as well as 








Example research areas for uncertainty 
mitigation 
I Tumor diagnosis 5 • Improved physiological, functional and 
cellular imaging 
II Tumor staging 5 • Tumor specific bio-markers 
III Tumor extent 4 • Improved physiological, functional and 
cellular imaging 
• AI/ML supported automatic contouring 
IV Patient specific 
sensitivity 
4 • Radio-sensitivity assays 
V Cellular response to 
radiation 
4 • Pre-clinical in-vitro studies 
VI Organ response to 
radiation 
4 • Organoid and small animal irradiations  
• Curative irradiation of spontaneous 
tumors in medium size animals 
• Multi-variate outcomes analysis 
VII Differential biology – 
protons/X-rays 
3 • Beyond RBE pre-clinical cell and small 
animal studies 
• Multi-variate outcomes analysis 
VIII Inter-fractional 
anatomical changes 
3 • Proton compatible on-board imaging 
• Fast and automated plan adaption 
IX Cyclical intra-
fractional changes 
3 • Near real-time, on-board, 2/3D imaging 
• Gating/Breath-hold/re-scanning 









































































• Ultra-fast delivery 
X Systematic intra-
fractional changes 
3 • Near real-time, on-board, 2/3D imaging 
• Fast and automated plan adaption 
• Ultra-fast delivery 
XI Patient positioning 2 • Comprehensive robust planning 
• Fast and automated plan adaption 
XII Residual range 
uncertainties 
2 • Dual energy/Photon counting CT 
• Proton CT 
• In vivo range verification 
• Comprehensive robust planning 
XIII Dose calculations 2 • GPU accelerated Monte Carlo 
 
XIV Machine delivery  1 • Improved position and dose monitoring 
• Faster monitoring, electronics and 
processing 
Table 1. A categorized list of uncertainties, together with a personal ranking of their relative clinical relevance. 5 is most 
relevant and 1 least relevant. Proton specific uncertainties are highlighted in italics. 
Advances in technology to meet challenges 
An overview off all the categories of uncertainties discussed above is shown in table 1, with a relative 
indication of the clinical relevance of each. Note, that this scale is not meant to be linear, and is also not 
meant to indicate that any area of research to mitigate these uncertainties is necessarily more important 
than any other. It just aims to put the uncertainties discussed here into clinical context. In addition, 
possible research topics for mitigating the categorized uncertainties are listed in the right-most column, 
with those where the solutions will be proton therapy specific highlighted in italics. As such, this table 
aims to provide a research and development roadmap for comprehensively reducing uncertainties in 
proton therapy. If successfully completed, these will substantially improve the quality and efficacy of 
what is an already a precise and successful treatment modality.       
Concluding remarks 
There are uncertainties related to every step of the proton therapy process, and eliminating them 
completely is impossible. However, through technological and methodological developments, 
improvements can be, and should be, made everywhere in an attempt to systematically reduce the 
uncertainty budget of proton therapy.   
 
Treatment planning for pencil beam scanning proton therapy 
Tony Lomax 
Status 
If the delivery machine is the heart of radiotherapy, then treatment planning is the brain. Whatever the 
capabilities of the beam delivery system, these can only be exploited to their clinical best by treatment 
planning systems that can fully explore the myriad of solutions to the treatment problem.  
However, as PBS proton therapy has only recently become clinically mature, we have only just begun 
to scratch the surface of the possibilities of PBS proton therapy, and to go deeper, many developments 
in the techniques and tools of treatment planning are required. Note, as robust and biological (RBE) 
planning have dedicated sections in this roadmap article, in this section we will concentrate on other 









































































areas for treatment planning development that need to, or will be pursued in the coming years. 
Current and Future Challenges 
One of the major characteristics of the treatment planning of proton therapy is its flexibility, where many 
solutions to the PBS planning problem provide superficially similar dose distributions to the target. As 
such, PBS proton treatments to the same case can vary enormously depending on the treatment planning 
system used, and the inputs provided. But this flexibility is a two-edged sword. On the one side, the use 
of different planning practices and tools at different institutes could lead to heterogeneous and perhaps 
contradictory clinical results, or make patient selection, when based on comparative planning exercises, 
inconsistent and potentially misleading (see article on “Selecting Patients for Proton Therapy”). On the 
other side, this flexibility is ripe for exploitation, for instance to substantially improve the quality or 
deliverability of proton therapy.  
Another major issue for proton therapy is its sensitivity to anatomical changes of the patient throughout 
the treatment course (Szeto et al 2016, Hoffman et al 2017). Ideally, methods to estimate these effects 
should also be incorporated in the treatment planning process in order to best mitigate (see section on 
adaption), or record, their effects on the delivered treatment (see article on “Adaptive Therapy”). Indeed, 
the issue of dose reporting, in the form of three-dimensional distributions of the estimated dose 
delivered to the patient, is a crucial, unique and perhaps undervalued attribute of radiotherapy and the 
treatment planning process. For instance, from such data, it is possible to build biological models 
predicting treatment outcome with ever increasing sophistication (see e.g. Wopken et al 2014), but 
models, which, in the end, can only be as predictive as the accuracy of the dose reporting itself. Thus, 
reporting of the actually delivered dose over the whole treatment course, rather than an estimate derived 
from a single calculation performed before the course commences, will become increasingly important.  
Finally, with the increasing investigation of new biologies with protons such as grid and FLASH 
irradiations (Mazal et al 2020), new and hitherto ignored delivery parameters, such as estimates of 
delivered dose rates and/or biological models estimating their effects, will need to be incorporated into 
the planning process (see article on “Delivery Technology”).       
Advances in technology to meet challenges 
Exploiting and taming flexibility: Much still needs to be done to fully exploit flexibility in PBS proton 
treatments. Obvious examples are developments in robust and LET based optimisation, both of which 
are covered in detail in other sections of this article (see also roadmap articles on “Robust Optimization” 
and  “RBE Clinical Impact”). However, an as yet, not fully exploited potential is the optimization of 
pencil beam placement within the field. For instance, as has been shown by Meier et al (2017), dose 
confirmation can be substantially enhanced using more flexible spot placement techniques such as 
contour scanning, where pencil beams are first placed on exactly the surface contour at any given depth, 
thus contracting the high dose contour closer to that of the target volume. Alternatively, spectacular 
reductions in the number of pencil beams per field, whilst preserving or even improving dose 
conformation, have been demonstrated through the inclusion of ‘spot reduction algorithms’ into the 
optimization process (van de Water et al 2013). Such approaches however can be considered to be just 
surrogates of the true ‘holy grail’ of PBS planning - the ability to flexibly and comprehensively include 
spot placement, spot size and delivery dynamics (e.g., energy switching layer and scanning times) 
directly into the optimization process, and much interesting work remains to be done in this direction.  
There is similar potential in the optimization of field directions and plan geometries. By plan geometries 
here, we mean the not necessarily trivial combination and overlapping of different fields during the 
planning process. For instance, one of the major advantages of the stopping characteristics of protons is 
the ability to significantly spare normal tissue through the use of ‘split fields’, whereby different fields 









































































cover different portions of the full target volume or volumes (see e.g. Lomax 1999, Widesott et al 2011)). 
In the future, such approaches will be included directly in a comprehensive optimization approach 
including both field directions and (if necessary) target splitting. Although it is clear that the degrees of 
freedom open to the optimizer for such an approach are huge, such developments will be pursued in 
parallel with the development of ultra-fast dose calculation engines (Matter et al 2019) which can 
efficiently and quickly search the huge solution space that is opened by such techniques. Indeed, such 
developments will also open the door to a more automated, and therefore consistent, approach to the 
treatment planning of PBS proton therapy, a solution that will also be augmented by developments in 
machine learning and knowledge based approaches to the treatment planning problem. Indeed, such 
developments may well be decisive in ‘taming’ degeneracy in treatment planning of PBS proton therapy, 
introducing planning consistency, thus enabling a more fair and effective method for selecting patients 
for proton therapy when working with (e.g.) model based approaches (see e.g Arts et al 2017 or Bijman 
et al 2017). As such, the current downside of the flexibility of PBS proton therapy - potential 
inconsistencies in plan quality between centers and plans - will be drastically reduced. 
Mitigating anatomical change: The mitigation of anatomical changes in proton therapy is particularly 
challenging for many sites, simply because the nature of those changes are difficult to predict. However, 
in some sites, anatomically robust optimization has been shown to be possible where such changes are 
localized and can be well modeled (Cubillos-Mesías et al 2018, van de Water et al 2018, Yang et al 
2020), and more developments are foreseen in this direction (see article on “Robust Optimization”). In 
particular, the use of morphological changes to the planning CT to model potential weight changes or 
physiological deformations (Kainz et al 2019) may have promise as future inputs to anatomical robust 
optimization approaches.  On the other hand, and as described in detail in another contribution to this 
article (see also roadmap article on “Adaptive Therapy” and Albertini et al 2019),  the management of 
anatomical change will move more and more into the direction of rapid, even daily adaption of the 
treatment to ‘anatomy-of-the-day’ volumetric image taken immediately before the delivery of each 
fraction.  
Such an approach poses a number of challenges, and opportunities, to the treatment planning process, 
such as the delineation of target and OAR’s on the daily volumetric data set, ultra-fast plan adaption or 
re-optimization, and efficient and automated plan verification tools. For target and OAR definition on 
the daily image set, either accurate and reliable deformable warping of the original volumes between the 
original plan and the daily patient geometry, or fully automatic delineation algorithms will need to be 
developed. Indeed, many advances have been made recently in the latter (Giraud et al 2019), and it would 
seem that this is the direction with the most promise in the future.  Even with this approach however, 
additional developments in treatment planning systems will need to be made in order to provide the 
clinician with feedback on the ‘plausibility’ of the automatically generated or deformed contours before 
applying the adapted plan, and such tools must be efficient enough to not substantially delay the adaptive 
process.    
Rapid plan adaption, such that a completely new or adapted plan can be calculated and validated in just 
a few minutes, will require developments in ultra-fast dose calculations and optimization, or 
alternatively, methods to determine and correct just those pencil beams of the original plan most affected 
by the changes (Botas et al 2018). Indeed, for adaptive plan optimization, different approaches can be 
foreseen. First, dose-restoration techniques may be used, whereby the plan-of-the-day is automatically 
adjusted to be as close to the original plan as possible, substantially mitigating the amount of plan specific 
validation and verification necessary (Bernatowicz et al 2018). Alternatively, tools for a full, ‘from 
scratch’ re-optimization, potentially involving beam angle adjustments as well, will be developed, which 
can additionally take into account any preferential features of the anatomy of the day, helping to possibly 










































































improve the quality of the treatment in relation to the original plan (Nenoff et al 2019). Similarly, and as 
proposed by Yan in his seminal paper on adapted therapy (Yan et al 1997) feedback loops could be 
incorporated into the adaptive process, whereby the accumulated doses from previous fractions are used 
as an input to the daily optimization process. This way, the ‘plan-of-the-day’ could also adapt on any 
deviations of the accumulated dose away from the reference plan (for instance as a result of interrupted 
previous treatments) or even capitalize on advantageous anatomical changes taking place over the course 
of the treatment (see e.g. Matter et al 2020). 
Finally, alternative, treatment planning based methods for plan validation will need to be developed, 
such as fast, fully independent dose calculations which can reconstruct the dose from (e.g.) machine 
control data before the plan-of-the-day is delivered (Matter et al 2019). Such developments will require 
an ever closer cooperation between the delivery machine and treatment planning system manufacturers 
(see article on “4D planning and Delivery”).  
Clinically relevant dose reporting: As we move towards treatment adaption to multiple imaging data 
sets of the patient, the problem of recording what dose was actually delivered to the patient at what point 
becomes increasingly challenging. However, such data is essential for the development of accurate 
biological models for outcome prediction (see article on “Outcome Modeling”). Although tools for 
registering two or more data sets together in 3 dimensions are mature, particularly for the deformable 
problem, the solution is notoriously degenerate, with different systems providing quite different 
solutions (Nie et al 2016; Nenoff et al 2020). As such, future developments in dose accumulation, 
together with associated ‘uncertainty’ maps indicating those regions where the accumulated dose can be 
trusted to a greater or lesser extent, will need to be developed (Heinrich et al 2016). This would be 
analogous to the calculation and presentation of dose uncertainty as part of robust plan analysis methods 
already available in most commercial treatment planning systems. Indeed, uncertainties of all types are 
an integral part of the radio- and proton therapy process, and as such can provide valuable information 
to the planning physician or also, eventually, as an additional parameter to include into outcome analysis 
and biological modeling. As such, dose reporting should also include standardized ways of reporting 
spatially varying uncertainties in calculated and delivered dose, as well as biological paramaters such as 
LET, both of which are important for proton therapy if we wish eventually to understand their clinical 
relevance. 
Planning for new biologies: Finally, it is perhaps too early to speculate on what changes to treatment 
planning systems will be required to plan for FLASH or Grid irradiations. For both, current dose 
calculation engines will likely be accurate enough to provide accurate estimates of the 3-dimensionally 
varying dose delivered to the patient. But given that the response of tissue to both techniques will be 
quite different to that of conventional therapy, even before we develop the appropriate biological models, 
new metrics for quantifying such plans will need to be developed. For FLASH, this will likely be in the 
direction of spatially varying spectrums of dose-rates (van de Water et al 2019, van Marlen et al 2020) 
which would, similarly to the validation of adaptive plans discussed above, require a close cooperation 
between treatment machine and therapy planning manufacturers. Based on these, and as our knowledge 
of the clinical FLASH effect becomes deeper, there will be the need to start to incorporate a biological 
‘FLASH’ effect as a function of dose rate, in an analogous way to RBE and its relationship with LET. 
Only through the development of such tools can we hope to be able to effectively plan FLASH 
treatments. For grid-based treatments, other tools may be necessary. As the sparing of normal tissue will 
be dependent on the peak-to-valley dose ratio and its spatial separation, treatment planning systems may 
need to provide tools for quantifying and optimizing this in an analogous way to dose volume histograms, 
or provide metrics for quantifying the heterogeneity (or ‘gridness’) of the dose distribution in normal 
tissues and the tumor.    










































































The relative immaturity of PBS proton therapy, together with the need to mitigate (and record) 
uncertainty, leads naturally to many challenging and interesting developments still to be done in the 
treatment planning of proton therapy. When also considering the exciting areas of FLASH and grid 
therapy, which are themselves challenging our conventional thinking of biology and what is a ‘good’ 
treatment plan, developments in treatment planning are anything but dead. Indeed, it is an area ripe to 
be exploited and where much still needs to be done.    
 
Development of robust planning 
Jan Unkelbach 
Proton therapy practitioners have long been aware of dose uncertainties in proton therapy and have 
developed strategies to account for uncertainty in treatment planning (Paganetti, 2011) (see article on 
“Uncertainties”). In the era of passive scattering based proton therapy, this included increasing range 
and modulation of spread-out Bragg peaks, widening apertures, and compensator smearing. For complex 
geometries requiring patch fields, multiple patch field combinations were used to mitigate the effect of 
misaligned fields. In the era of pencil beam scanning, treatment planning became based on mathematical 
optimization techniques similar to intensity-modulated radiotherapy (IMRT). The similarity to IMRT 
made it natural to apply the planning target volume (PTV) concept to proton therapy planning. However, 
it was soon realized that the PTV concept has limitations in proton therapy. The fundamental assumption 
behind the PTV concept, that the CTV receives the prescribed dose as long as it moves within the PTV, 
is not generally valid for proton therapy. Range and setup errors may lead to misalignment of dose 
contributions of different beams, misalignment of tissue heterogeneities in the entrance region may 
degrade dose distributions, and thus PTV coverage does not guarantee CTV coverage even if PTV 
margins are large. A commonly used heuristic to improve robustness is referred to as single field uniform 
dose (SFUD), which mitigates dose degradation due to misalignment of dose contributions from 
different beams. However, for complex shaped target volumes, SFUD compromises treatment plan 
quality compared to intensity-modulated proton therapy (IMPT). In addition, dose degradation due to 
misalignment of tissue heterogeneities is not addressed. Robust optimization methods were developed 
to address these limitations and refer to mathematical optimization techniques that directly incorporate 
uncertainty into the formulation of the IMPT optimization problem.  
Status of robust optimization 
Robust planning can be divided into robustness evaluation (i.e. assessing the sensitivity of a given 
treatment plan to errors) and robust optimization (i.e. the process of obtaining a treatment plan that is 
robust against errors). In photon therapy, robustness is indirectly assessed by evaluating the dose 
distribution in the PTV. As it has been recognized that coverage of the PTV does not guarantee coverage 
of the CTV in proton therapy, the main commercial treatment planning systems (TPS) now allow for 
evaluating the dose distribution for individual error scenarios. In addition, various measures to assess 
dose uncertainty such as confidence intervals around DVH lines have been suggested but only a subset 
of those is available for practitioners. In addition, the main TPS have an implementation of robust 
optimization. (see article on “Treatment Planning”) 
In IMPT optimization, an objective function 𝑓, which is a function of the dose distribution 𝑑, is 
minimized with respect to pencil beam intensities 𝑥. Under uncertainty, given pencil beam intensities 𝑥 
may lead to different dose distributions 𝑑$ for error scenario 𝑠. Practically, the goal is to obtain a 
treatment plan that is of high quality for all or most anticipated errors. There have been three approaches 










































































to translate this practical goal into mathematical terms that led to implementations in the main 
commercial TPS.  
1. Stochastic optimization, also referred to as probabilistic treatment planning, assigns probabilities 
𝑝$ to the error scenarios and optimizes the expected plan quality (Unkelbach et al., 2009). This 








2. Minimax optimization (Fredriksson et al., 2011), also referred to as composed worst case 
optimization, determines the pencil beam intensities such that the dose distribution is as good as 
possible for the worst error scenario considered. Minimax optimization is implemented in 
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3. Optimization of the voxel-wise worst case dose distribution (Pflugfelder et al., 2008) can be 
considered a variation of minimax optimization. Here, the minimum doses in target voxels and the 
maximum doses in normal tissue voxels are considered. The resulting voxel-wise worst-case dose 
distribution is used for evaluating the objective function. The approach is implemented in Eclipse 
(Varian).  
Other methods, such as minimax stochastic optimization (Fredriksson, 2012), which interpolates 
between optimizing average and worst-case plan quality, have been proposed, but are currently not 
available for practical use in commercial systems. An extensive review is provided elsewhere 
(Unkelbach et al., 2018). For illustrations of robust optimization and comparisons to PTV-based plans, 
we refer to the original publications. The variety of methods implemented in different commercial 
systems suggests that there is no single robust planning method that is found to be generally superior. It 
has been shown that individual methods have disadvantages in specific situations, however, in most 
cases different robust planning yield very similar results. Publications comparing methods are scarce. 
Regarding the types of uncertainty, most of robust IMPT planning research has focused on systematic 
range and setup errors. In the research literature, extensions to other uncertainties such as respiratory 
motion have been considered but are only partially supported in some TPS. (see articles on “Treatment 
Planning” and “4D Planning and Delivery”) 
Current limitations and future challenges 
Establishing consensus for robustness evaluation: In photon therapy, plan robustness is indirectly 
assessed by evaluating coverage of the PTV. Although this may have limitations also in photon therapy, 
it allows for establishing consensus that is needed, for example, in the design and reporting of multi-
institutional trials. Concepts for robustness evaluation for protons have been proposed (Korevaar et al., 
2019). However, there is no general consensus yet on how to assess and report the robustness of proton 
plans, which should be addressed in future working groups. 
Optimization based on relevant plan quality indicators: Most robust optimization methods currently 
available were developed by applying known methods from the optimization literature such as minimax 
or stochastic optimization to the IMPT planning problem. Thereby, common objective functions such as 
quadratic penalty functions are robustified. However, the expectation or worst-case values of quadratic 









































































penalty functions are only surrogates for plan quality. In practice, DVH based criteria are considered, 
for example, a treatment plan may be acceptable if 95% of the target volume receives the prescription 
dose in 90% of the scenarios. Future work may aim at facilitating robust treatment plan optimization 
using relevant plan quality indicators as objective and constraint functions. 
Beyond systematic range and setup errors: Current research and support in commercial systems has 
focused on systematic range and setup errors. Typically range errors are modeled by up- or down-scaling 
of Hounsfield units of the planning CT. Thereby, it is assumed that range errors affect all pencil beams 
in the same way, that is, all pencil beams overshoot or undershoot synchronously. Setup errors are 
modeled as rigid shifts of the patient. These models of uncertainty are simple to implement, however, 
the real source of uncertainty is more complex. Today, range and setup errors are used as surrogates for 
other uncertainties such as internal organ motion (see articles on “Adaptive Therapy” and “4D Planning 
and Delivery”). Complex geometric variation is difficult to model based on a single planning CT scan 
prior to treatment. Nevertheless, future work may consider the development of site-specific uncertainty 
models for evaluation and optimization that reflect the characteristic uncertainty of specific treatment 
sites (see article on “Treatment Planning”). 
 
Figure 1: Illustration of stochastic programming applied to parameter uncertainty in RBE models. A 
simple model for RBE-weighted dose, 𝑅𝐵𝐸 ∙ 𝑑 = (𝑐0 	+ 𝑐2	𝐿𝐸𝑇) ∙ 𝑑, is considered. RBE uncertainty is 
modeled via 3 scenarios: 1) a constant RBE of 1.1 𝑐0
$ = 1.1, 𝑐2
$ = 0 , 2) a variable RBE with 
𝑐0
$ = 1.0, 𝑐2
$ = 0.04	µm/keV . This corresponds to the assumption that the RBE of a proton pencil beam 
is 1.0-1.1 in the entrance region, 1.2-1.3 near the Bragg peak, and 1.5-1.6 in the falloff region. 3) an 
intermediate scenario 𝑐0
$ = 1.05, 𝑐2
$ = 0.02	µm/keV . An RBE-weighted dose of 54 Gy(RBE) is 
prescribed to the target volume, and 57 Gy(RBE) was allowed in parts not overlapping OARs. Figure 1a 
(bottom row) demonstrates the problems with conventional planning based on a RBE of 1.1. When 
evaluated for variable RBE, hot spots >60 Gy(RBE) in OARs overlaying the target can be observed, 
resulting from high LET. Figure 1b (top row) shows issues with IMPT optimization based on a fixed 
RBE model. The method leads to lower physical doses in parts of the target, potentially leading to 
underdosage (<50 Gy(RBE)) if the LET effect on RBE is overestimated by the model. Figure 1c shows 
that robust optimization incorporating RBE uncertainty yields adequate target dose distributions in both 
situations. 









































































Computationally efficient methods: Robust optimization remains a computationally demanding task, 
depending on the number of scenarios considered, and may lead to long computation times. Several 
approaches to address computation time are being investigated and may be brought to an application in 
the future. Perko et al. (2016) developed a methodology allowing fast robustness evaluation of treatment 
plans. In their approach, the dose distribution is evaluated for a limited number of error scenarios; 
subsequently, these dose distributions are fit with a set of polynomial basis functions. Thereby, a model 
of the dose distribution as a continuous function of the error is obtained, which can be used for further 
robustness evaluation at almost no additional computation time. Bangert et al. (2013) pursue an 
alternative approach to probabilistic treatment plan evaluation and optimization going beyond a discrete 
set of error scenarios. The underlying idea is to consider Gaussian range and setup errors in combination 
with a Gaussian parameterization of pencil beam dose distributions. In that situation, one can exploit the 
fact that the convolution of Gaussian functions can be done analytically. This allows, for example, 
efficient evaluation of the expectation and variance of the dose distribution. 
Applications to biological uncertainties: So far, robust optimization was mostly investigated for 
geometrical uncertainty. In parallel, treatment planning methods to account for variable relative 
biological effectiveness (RBE) have been researched. This includes treatment plan optimization based 
on RBE-weighted dose (Wilkens and Oelfke, 2005), but also methods to incorporate linear energy 
transfer (LET) into IMPT optimization (see article on “Relative biological effectiveness”) . One of the 
challenges in this domain is the uncertainty in RBE. Some LET-based methods can be understood as 
heuristics to make IMPT plans robust against uncertainties in RBE. However, an alternative is to apply 
robust optimization techniques to account for uncertainty in the parameters of an RBE model (Unkelbach 
and Paganetti, 2018). This is illustrated in Figure 1 for an atypical meningioma patient in whom the 
target volume (red) overlays the brainstem (green) and the optic nerves (yellow). 
Concluding remarks 
Robust planning support is implemented in the main commercial TPS for proton therapy. Thereby, robust 
optimization has matured from a research topic to a technique that is routinely used for treatment 
planning in clinical practice. Future work in this domain may aim at establishing consensus for 
robustness evaluation and reporting, facilitate robust optimization based on such agreed-upon robust 
plan quality indicators, develop site specific uncertainty models beyond systematic range and setup 
errors, and reduce computation times for robust planning.  
 
Adaptive Therapy to Account for Daily Anatomy and Range Variations  
Lei Dong and BK. Kevin Teo 
Status 
It is well recognized that the proton therapy dose distributions are more sensitive to patient’s anatomic 
changes (Engelsman et al., 2013; Muller et al., 2015; Hoffmann et al., 2017) (see article on 
“Uncertainties”) compared to photon therapy. Adaptive radiation therapy (ART) is becoming a critical 
tool for some treatment sites, such as head & neck (Muller et al., 2015; Gora et al., 2015) and lung 
cancers (Gomez and Chang, 2011; Hoffmann et al., 2017) which are known to have large anatomical 
changes during treatment course due to treatment effects, such as tumor shrinkage, weight loss, pleural 
effusion, atelectasis etc. It is a common practice to repeat the simulation CT to evaluate patient’s 
anatomical changes and re-calculate the original proton plan on the updated CT or 4DCT images to 
assess target coverage and normal tissue sparing. When necessary, offline ART is performed to improve 
dose conformality. 








































































Unlike photon therapy, there are additional factors that can trigger a proton plan adaptation. For example, 
changes outside of the target volume, which include but are not limited to radiological pathlength 
variations due to patient’s anatomy, changes of couch top or immobilization devices relative to the 
simulation position, heterogeneity changes etc. While robustness optimization is a planning strategy to 
manage potential rigid setup errors and expected range variations, ART is a personalized approach to 
deal with actual changes during treatment. 
Although offline ART is becoming a common practice in proton therapy, it is still a time- and resource-
consuming process. The primary steps in ART include re-simulation, re-contouring, original plan 
evaluation, and re-plan (ART) if necessary, with the associated quality assurance procedures for new 
plans. While some of these steps can be assisted by auto-segmentation or auto-planning tools, human 
intervention is still required because these tools are not perfect and there are many required steps (such 
as manual importing images, physician’s availability and adequate time to review plans etc.), even if 
computational resources are not a constraint. There are no clear guidelines on how often patients should 
be evaluated for anatomical changes or well-defined criteria that should be used to trigger ART. 
Nevertheless, in-room volumetric imaging using CBCT or CT-on-rails has become a standard 
configuration for modern proton therapy (Landry and Hua, 2018); qualitative or quantitative evaluations 
of patient’s anatomy have become more convenient. This trend of using online volumetric imaging 
should increase the utilization of ART for proton therapy in the near future.  
Current and future challenges 
ART is an interventional process that requires adequate feedback (online/offline imaging), decision 
support (criteria for replanning) and corrective strategies. The general process and selected contents 
specific to proton therapy are summarized in Figure 2. It is important to realize that there are many 
factors that can impact conformal dose delivery. Proton ART may be limited by the correction strategies 
(offline, online or real-time) or imaging techniques to detect specific changes in patients. An offline ART 
approach can correct systematic or slow changes in anatomy, but may be limited in adapting daily 
physiological variations in setup 
position.  
Figure 2: Adaptive Proton 
Therapy is an interventional 
process that requires imaging 
and algorithms to detect changes 
and identify improvements, and 
then a subsequent corrective 
strategy. 
Although the offline ART seems 
to be a practical approach, the 
process itself can benefit from 
streamlining and automation in 
many steps: CT image artifact 
removal, density overrides for 
couch/immobilization structures, auto-contouring of targets and organ at risks (OARs), faster dose 
calculation and plan comparison tools. If a new ART plan is requested, a faster treatment optimization 
and efficient QA may be needed. Sometimes, transferring the approved plan to vendor’s treatment 
console and updating treatment calendar for the new plan would require additional manual intervention. 
Because this is a time-consuming manual process, few proton therapy patients are currently benefiting 









































































enough from offline ART. For those centers that do, imaging frequency, contouring, and quality of ART 
plan may be suboptimal due to time constraint and resource limitations. Therefore, the current biggest 
needs are the development of automation tools that can support proton ART workflow. 
Figure 3: Scoring sheet for common online/offline correction strategies and their corresponding 
uncertainties. WET: Water-Equivalent-Thickness; OAR: Organ-At-Risk. 
Recently, there has been enormous progress in 
developing online adaptive photon therapy (Wang et al., 
2017). Some of these tasks are identical for proton ART 
(for example, auto-segmentation on CT or CBCT 
images) while others share a similar approach. For 
example, the use of GPU for fast dose calculation or plan 
optimization (Matter et al., 2019), and quality assurance 
(Wang et al., 2017), which are critical for online ART. 
Near real-time dose restoration to account for daily tissue 
density variations using an on-line range adaptation of individual spot energies (Zhang et al., 2011) with 
readjustment of some spot weights (Jagt et al., 2017) is one approach that permit fast plan re-generation 
for online ART (see section on Treatment planning for pencil beam scanning proton therapy). A 
summary of proton ART strategies and correction goals are listed in Figure 3. 
A more difficult problem is to convert Hounsfield Unit (HU) from online CBCT images into accurate 
proton stopping power ratios that are required for dose calculation. Some investigators used a virtual CT 
approach, which matches CBCT HU to the corresponding simulation CT images using a deformable 
image registration method (Veiga et al., 2016) and others used scatter correction to create a high quality 
CBCT similar to the conventional CT scanner (Nomura et al., 2019). Recently, machine learning based 
approaches seem promising in directly converting CT numbers into proton stopping power (Nomura et 
al., 2019; Kurz et al., 2019). Each of these approaches creates additional uncertainties, which should be 
factored in the implementation of ART. 
An ideal approach for online ART might involve the use of in vivo imaging for proton range correction 
(see article on “In vivo range verification”).  Because range uncertainties are the primary reason for plan 
adaptation and also responsible for suboptimal quality in the original plan due to uncertainties in proton 
stopping power conversion (Yang et al., 2012), an online range-adapted proton therapy approach would 
be appealing if the proton range can be accurately detected and corrected just prior to treatment delivery. 
In vivo range detection is still under intense research, and investigated approaches include but are not 
limited to (1) in-room proton CT (Sadrozinski et al., 2016); (2) prompt gamma detection (Hueso-
Gonzalez et al., 2018; Xie et al., 2017); (3) proton radiography (Deffet et al., 2017); (4) proton-acoustic 
wave detection (Patch et al., 2019) etc. If successful, one additional benefit is to use the sharp falloff of 
the Bragg peak to spare distal OAR, which has not been fully utilized in conventional proton therapy 
due to range uncertainties (Hoesl et al., 2016). Data from in vivo imaging can be used in two ways. First, 
if systematic range shifts due to inaccuracies in proton stopping power are detected, the plan may be 
adapted to reduce these shifts for subsequent fractions. Second, in vivo range verification offers a real-
time quality assurance of the online ART plan when traditional measurement-based QA with phantom 
is not feasible.    
Other challenges are related to the rapid variation of proton range due to breathing motion and beam 
interplay effects (Mori et al., 2018). For treatment sites that experience a large organ motion, 4D 
cumulative dose calculation may be needed to evaluate plan robustness for both inter- and intra-fractional 
changes (Li et al., 2012) (see article on “4D planning and delivery”). ART planning may need to 
incorporate plan robustness to minimize motion effects (Liu et al., 2016). ART planning can also be used 









































































to compensate patient specific motion patterns (Li et al., 2015).  
Concluding remarks 
Due to many technical and practical issues, proton ART is in its infancy. The biggest challenge now is 
to develop reliable tools (such as data processing, informatics, plan review, decision support, auto-
planning, quality assurance etc.) to make the entire process more efficient and practical. Currently, there 
is no consensus on what anatomic or dosimetric change would be required to trigger ART that will 
optimize the treatment. However, the dosimetric benefit of proton ART is well accepted by the proton 
therapy community. Parallel to the development in photon therapy, online proton ART is the upcoming 
strategy that can bring perhaps the biggest dosimetric benefit to proton therapy patients (Albertini et al., 
2019). Ultimately, the success of ART has to be associated with improved clinical outcome. For 
example, Yang et al. demonstrated that ART improved 5-year overall survival for a subgroup of lung 
cancer patients with poor initial conditions (i.e., large tumors), presumably due to improved dose 
conformality (Yang et al., 2019), although more studies are needed.    
 
In vivo range verification  
Katia Parodi 
Status 
Already back in the early pioneering phase of proton therapy, Bennett et al postulated the possibility of 
controlling the surface of maximum beam penetration, which relates to the ability of depositing the dose 
maximum (Bragg peak) in the tumor while sparing the normal tissue behind, by visualizing the b+-
activity generated through nuclear interactions of protons in tissue (Bennett et al 1978). Their seminal 
work not only showed that a prototype on-line positron emission planar camera was able to visualize in 
a live pig the pattern of proton-induced activation, which was mostly ascribed to 11C, 15O and 13N 
fragmented tissue nuclei, but also foresaw the use of such positron emission measurements for 
reconstruction of the delivered dose. Moreover, they emphasized the importance of on-line detection for 
analysis of the biological transport of irradiation-induced radionuclides, which is relevant to the 
localization and reconstruction of the delivered dose, and even suggested to provide useful information 
on regional blood flow. Nevertheless, due to the technological challenges for development and 
integration of dedicated positron-emission-tomography (PET) scanners in the treatment delivery, most 
of the following investigations in phantoms and first clinical pilot studies were pursued after treatment 
using nuclear medicine PET and PET/CT (computed tomography) full-ring diagnostic scanners (Parodi 
and Polf 2018). Such in-room and offline volumetric imaging approaches suffer from issues of physical 
and biological decay in the time elapsed between irradiation and imaging, along with possible changes 
of the patient position, all degrading the correspondence between the physically produced and the image 
reconstructed activity (Parodi and Polf 2018, Shakirin et al 2011). Although most of these issues can be 
overcome with the ongoing re-implementation of on-line detection approaches (Parodi and Polf 2018, 
Shakirin et al 2011, Ferrero et al 2018), the PET signal can be considered intrinsically delayed with 
respect to the beam delivery according to the half-life of ~2-20 min of the most abundant positron 
emitting reaction products. Hence, in 2003 Stichelbaut and Jongen raised the question why not verifying 
the proton beam position in the patient by the detection of prompt gamma (PG) rays emitted in the very 
fast (sub-ns scale) de-excitation processes after nuclear interaction (Krimmer et al 2018). However, due 
to the high energies of such PG emissions in the MeV range, it took several years of computational 
simulations and detector development (Krimmer et al 2018) to arrive at first viable prototypes of 
collimated cameras (Xie et al 2017, Hueso-González et al 2018), only able to capture a one- or two-
dimensional projection of the distal PG signal generated from each individual pencil beam delivered to 









































































the patient. Remaining challenges entail further improvements of detector technologies along with 
interpretation and utilization of these (or even other) secondary emissions, typically in comparison to an 
expectation, to devise new strategies for ideally real-time beam range verification and quantification of 
the actual dose delivery for prompt treatment adaptation. These efforts will also largely benefit from as 
well as complement the ongoing developments in in-room volumetric and even time-resolved anatomical 
image guidance (see article on “Image Guidance”). 
Current and future challenges 
State-of-the-art on-line PET and PG detectors are just entering the phase of clinical evaluation with the 
most modern form of scanned proton beam delivery. At the combined proton and carbon ion therapy 
facility of CNAO (Centro Nazionale di Terapia Oncologica) in Italy, a dual-head PET scanner based on 
modern scintillation crystals (Lutetium fine silicate) and photosensors (multi-pixel photon counters) is 
used to dynamically (every »10 s) reconstruct the irradiation induced activity during treatment, with very 
promising initial clinical results (figure 4) (Ferrero et al 2018). Here, a major challenge is the still 
outstanding ability of using the events measured during the actual beam delivery (spills), due to 
remaining background from prompt radiation (including PG), despite a dedicated data acquisition system 
aiming to suppress it. Moreover, reconstruction and visualization of the data acquired during the 
interrupts (pauses) of the synchrotron-based beam delivery still requires 6 seconds, impeding a truly real-
time imaging. It seems possible to achieve sub-mm reproducibility of distal range measurements in 
different treatment days, but accuracy between PET measurements and predictions remains at the still 
unsatisfactory level of a few millimeters (figure 4) (Fiorina et al 2018), thus demanding further 
improvements of the underlying modeling. The ongoing clinical evaluation and further methodological 
improvements will thus enable assessing whether the desired range localization accuracy of less than 1-
2 mm can be achieved, going beyond the reported accuracy of PET-based verification in the order of 2-
5 mm for the earlier less optimal clinical implementations (Parodi and Polf 2018; Parodi 2018). 
Figure 4:  Example of the 
dedicated in-beam PET 
scanner in treatment 
position at CNAO (a) and 
the dynamically 
reconstructed PET 
activation data in 
comparison to the 
simulated predictions (b) 
in two different time 
windows during proton beam delivery. The PET images (color wash) are superimposed onto the planning 
X-ray CT (grey scale). Adapted from (Fiorina et al 2018), with permission.  











































































Figure 5 (a) Schematic of the knife-edge slit camera, as deployed in the first clinical study of (Xie et al 
2017), projecting the PG signal (green) from the proton beam (blue) onto the position sensitive 
scintillators beyond the collimator. The corresponding analysis results in the spot-by-spot (with 
aggregation) range difference comparison in beam-eye-view (b) as well as PG-based estimation of the 
measured (green) and predicted (red) Bragg peak depth overlaid with the planning CT (c) for a given 
energy layer and treatment fraction. Adapted from (Xie et al 2017, with permission from Elsevier). 
For PG, two prototypes of a single slit camera, consisting of a knife-edge collimator and position 
sensitive Lutetium-yttrium oxyothosilicate scintillators readout by silicon photomultipliers (Krimmer et 
al 2018, Xie et al 2017), are being investigated for their ability of spot-by-spot proton range recovery at 
University of Pennsylvania (figure 5) and University Proton Therapy Dresden. The initial clinical 
evaluation showed the feasibility of achieving precision (defined as standard deviation of random 
simulated shifts) within 2 mm when aggregating the signal from nearby pencil beams for sufficient (³ 
1.2 108 protons) counting statistics. However, the clinical findings of average (aggregated over all spots 
in 9 energy layers) range shifts from -0.8 mm to 1.7 mm between measurement and expectation were 
mostly limited by the mechanical accuracy of the trolley positioning system, for which improvements 
are currently ongoing. Still, the design of this detection system can only provide one-dimensional profiles 
of coarse spatial resolution, challenging the performance in the presence of considerable tissue 
heterogeneities that distort the distal dose surface, or large tumor sizes that require a wide dynamic range 
of the camera field-of-view coverage. More recently, another collimated system featuring eight LaBr3 
scintillators behind a tungsten collimator, mounted on a rotating frame, has been thoroughly 
characterized experimentally prior to its clinical deployment (figure 6) (Hueso-González et al 2018). 
The detection system has been optimized for energy and time resolution to enable spectroscopic analysis 
of the gamma emissions characteristics of each specific tissue nuclei and for optimal suppression of 
radiation background outside the microscopically bunched beam extraction from the cyclotron. By 
comparing the measured signal with a sophisticated prediction model taking into account experimental 
data of PG emissions for different nuclear reaction channels as well as possible range error scenarios, 
the system can provide spot-by-spot maps of range difference (between measurement and prediction) 
and percentage elemental composition of carbon and oxygen (figure 6). Investigations in phantoms 
suggested the feasibility to retrieve the proton beam range with a mean statistical precision of 1.1 mm at 
a 95% confidence level and a mean systematic deviation of 0.5 mm (Hueso-González et al 2018). Hence, 
this level of accuracy, if confirmed in the ongoing first clinical evaluation, would be well below the one 
so far reported for PET-based range verification. However, also this system requires aggregation of 
neighboring spots to increase the signal statistics, thus challenging the achievable spatial resolution and 
range resolving power in the presence of pronounced tissue heterogeneities. Moreover, none of these on-
line PET and PG systems integrates imaging modalities able to provide complementary information on 
the tissue anatomy, for co-registration with the retrieved information of the distal beam penetration depth 








































































as well as updated patient model for attenuation (and scatter) correction. 
Figure 6: Schematic of the spectroscopic system of (Hueso-González et al 2018) integrated in the proton 
beam gantry for a representative treatment position (a), along with the details of the energy- and time-
resolved detector components beyond the collimator (b). The results enable quantifying the range 
difference from a prediction model for each applied spot (c) along with carbon (d) and oxygen 
concentrations, in this example obtained when inserting a slab phantom on the left of the beam path in 
water (with spot aggregation). Adapted from (Hueso-González et al 2018). 
 
Advances in science and technology to meet challenges 
Ongoing research in the medical imaging community towards detectors of ultra-fast timing resolution in 
the order of 10 ps, along with steady progress in real-time data acquisition and processing, will certainly 
benefit the above described detector designs, ideally enabling real-time imaging as well as improved 
background suppression and image quality (Lecoq et al, 2020). For PET-based range verification, 
additional efforts are ongoing to exploit the signal from millisecond short-lived positron emitters (e.g., 
12N) to enable quasi real-time visualization of the dynamic beam delivery (Buitenhuis et al 2017), 
although likely at the expense of degraded spatial resolution from the typically long positron range. For 
PG imaging, efforts are ongoing to increase the dimensionality of the reconstructed distribution and to 
remove the massive collimator for enhanced detection efficiency. To this end, several prototype designs 
of Compton cameras have been proposed based on different detector technologies (solid state, 
scintillation, and thereof combination), along with alternative approaches exploiting only the arrival time 
of the photons or their conversion into secondary electrons (Krimmer et al 2018). Exploitation of the 
Compton kinematics also opens the perspective of new unconventional designs of hybrid detection 
systems able to reconstruct signals related to standard PET and PG emissions, as well as triple 
coincidences originating from special isotopes (e.g., 10C, 14O) that emit an additional third photon in 
connection with their radioactive decay (Lang et al 2014). Besides utilization of complementary photon 
emissions (e.g., PG during beam-on and PET during beam delivery pauses or after irradiation), triple 
gamma imaging offers the intriguing potential of visualizing the underlying activity with only a few 
detected events, thereby also opening the perspective of an almost real-time imaging, at the expense of 
the lower probability of such events (Lang et al 2014). This ability could also be exploited to combine 
in-vivo range verification with additional nuclear tracer imaging for localization of the tumour or specific 
biomarkers to provide image-guidance during treatment, ideally also time-resolved for moving targets. 
Regardless of the final technological implementation and imaging approach, information on the in-vivo 
range will likely still rely on a comparison between the measured and predicted signal. To this end, 
considerable progress is expected from the emerging ability of embedding fast predictions of PET and 









































































PG signals in treatment planning engines (Pinto et al 2020), which also enables accounting for the 
counting statistics required for reliable monitoring in the treatment planning approach (Tian et al 2018, 
2020). Improved accuracy of these computational models will also largely benefit from the ongoing 
efforts of the scientific community to provide more accurate experimental measurements of underlying 
nuclear cross section data and resulting PET and PG yields in clinically relevant targets (Horst et al 
2019). Moreover, advances in artificial intelligence and deep learning approaches will also support the 
implementation of novel and fast workflows which can provide almost real-time feedback on the dose 
delivery (Liu et al 2020) to devise prompt correction strategies even during patient irradiation.  
Concluding remarks 
The considerable ongoing progress in instrumentation and computational methods for PET and PG 
imaging will likely enable reliable and almost real-time (sub)millimeter accurate monitoring of the beam 
range in the patient in the near future, which would be a major step forward with respect to the so far 
attempted applications of these technologies in clinical pilot studies. Although PG can offer advantages 
in terms of range localization accuracy and real-time information, PET provides an intrinsically 3D 
imaging modality lending itself to the possible combination with tracer imaging. Imaging annihilation 
and single photon emissions with a single device (Yoshida et al 2020) will open new prospects for 
making the most of both technologies during different portions of the irradiation (e.g,. PG during beam-
on and PET during beam-off) and evaluate their strengths and limitations in different anatomical sites. 
These nuclear-based technologies of general applicability, already finding their way into clinical 
translation, will likely be complemented by the less mature technologies currently under investigation 
for specific anatomical locations, using different kinds of secondary emissions (e.g., thermoacoustics for 
pulsed beams or secondary protons) or pre-treatment range probes (Parodi and Polf 2018). All these 
efforts in range verification will also benefit from and complement the ongoing developments for 
improvement of the daily patient model at the treatment place based on different flavours of X-ray, 
proton and magnetic resonance and, especially in the case of thermoacoustics, ideally intrinsically co-
registered ultrasound imaging (see articles on “Image-guidance” and “Adaptive therapy” as well as 
Parodi (2018)). Together with the further development of very promising methods of dose reconstruction 
from the measured emissions (Masuda et al 2019), advances in the monitoring of proton treatment will 
provide real-time information of the beam position in the patient and ideally of the applied pencil-beam 
dose in the underlying updated patient anatomy, for prompt interruption of erroneous delivery or new 
adaptive treatment schemes. Also, changes in the detected signals over the course of fractionated therapy 
could be exploited to monitor processes correlated to treatment response, such as biological washout 
(e.g., accessible with PET imaging, as already shown in the seminal work of Bennett et al 1978) or 
oxygen concentration (e.g., accessible with PG spectroscopy) (Parodi and Polf 2018), as recently 
reported for phantom studies by (Martins et al 2020). This would thus open a new dimension of biology-
driven treatment personalization, beyond the more physics-driven scope of range monitoring and dose 
reconstruction for truly adaptive therapy. 
 
4D planning and delivery  
Antje-Christin Knopf 
Status 
By now the great majority of new proton therapy (PT) centers is equipped with pencil beam scanning 
(PBS) solely. The high precision of PBS-PT comes as a double-edged sword, especially for moving 
targets. Highly conformal dose distributions have to be delivered in a robust manner to address the high 
sensitivity of PBS-PT to uncertainties. Over the past few years, treatments for lesions with intra-fraction 









































































motion significantly increased in number due to the availability of robust optimization, evaluation and 
quality assurance tools, increasing confidence. However, the influence of uncertainties has to be further 
minimized to exploit the full benefit of PBS-PT for moving indications of all characteristics. 
Current and future challenges 
4D imaging: Inter-fractional variations of breathing pattern and patient anatomy introduce dose 
uncertainties in PT. Only in recent years, with the introduction of in-room computed tomography (CT) 
and cone-beam CT (CBCT) for patient positioning, it has become feasible to monitor these variations 
without relying on external surrogates (Landry and Hua 2018). However, to make more use of the daily 
acquired CBCTs for daily 4D dose recalculations, 4D reconstruction and 4DCBCT-based 'virtual 4DCT' 
generation has yet to be established and to be implemented clinically. So far, the use of 4DCBCT for 
adaptive PT for lung cancer has been studied in silico (Veiga et al 2016). Also, in a phantom setting the 
feasibility of 4DCBCT-based proton dose calculation has been demonstrated (Niepel et al 2018).  
Intra-fractional variations, occurring during beam delivery, still can only be monitored by external 
surrogates and thus remain largely undiscovered. The broader clinical implementation of fluoroscopy 
during beam on might give intra-fractional insights using internal surrogates (Shirato et al 2012). Future 
developments towards combined MR-PT machines might enable full 4D online monitoring. 
4D optimized planning: 4D optimized planning has recently become available in commercial treatment 
planning systems (Engwall et al 2018). Several studies have shown that the incorporation of respiratory 
motion, along with setup and range uncertainties, into 4D robust optimization, has the potential to 
improve the resilience of target and normal tissue dose distributions in PBS-PT plans in the face of the 
uncertainties considered (Liu et al 2016, Cummings et al 2018, Ge et al 2019). However, 4D optimized 
planning remains computationally expensive and time consuming, requiring further developments to 
make it more widely usable in clinical routine (Pepin et al 2018). Furthermore, the impact of different 
deformable image registration (DIR) algorithms (Ribeiro et al 2018) and the physical correctness of dose 
accumulation remain topics of concern for 4D optimized planning (see article on “Treatment Planning”).  
4D evaluation: Papers addressing the robustness evaluation of PBS-PT plans for moving indications 
mainly report on the impact of setup and range errors, breathing motion and interplay individually. Only 
recently also studies on the combined impact of different uncertainties have become available (Inoue et 
al 2016, Ribeiro et al 2019). These comprehensive 4D robustness evaluation methods are essential to 
safely extend PBS-PT to moving indications. They allow the assessment of full PBS-PT treatment 
courses for moving targets, helping to define optimal clinical protocols for this group of patients. 
4D delivery / motion mitigation: While in a research context all kind of sophisticated motion mitigation 
approaches like phase-correlated rescanning (Ogata et al 2014), multi-gating (Graeff et al 2014) or 
tracking (Zhang et al 2014) have been discussed, the vast majority of PBS-PT centers treating moving 
indications relies on simple motion mitigation approaches. It has been stated that for motion amplitudes 
< 5mm rescanning might be sufficient to assure robust treatments of moving targets (Jason et al 2018). 
For larger motion amplitudes techniques are preferred that reduce the motion extent. Respiratory gating 
and breath-hold techniques are theoretically desirable but logistically challenging, especially in large 
centers with a single proton source/accelerator and multiple treatment rooms and in patients with poor 
lung function. While still being investigated, the use of mechanical ventilation, may be a promising way 
forward for the delivery of proton therapy (Jason et al 2018, Van Ooteghem et al 2019). 
4D adaptive therapy: During the course of fractionated radiotherapy, deformational and mass changes 
associated with regression of the visible tumor occur frequently. These changes often also affect the 
motion characteristics of the tumor and the surrounding tissue. Prospective pretreatment evaluations only 
provide multi-scenario predictions without giving a clear patient-specific conclusion for the actual PBS-










































































PT treatment. To provide robust treatments, especially with highly sensitive proton therapy, adaptive 
workflows have been suggested (Chang et al 2017). 
To facilitate treatment quality evaluation and to support decisions regarding plan adaptation, fraction-
wise retrospective four-dimensional (4D) dose reconstruction and accumulation aiming at the evaluation 
of treatment quality during and after treatment has been implemented (Meijers et al 2019). The described 
approach considers the influence of changing patient anatomy and variations in the breathing pattern by 
using treatment delivery log files and breathing pattern records of each fraction as well as most recent 
available imaging information to reconstruct and accumulate the actual delivered 4D dose. Treatment 
delivery log are produced by the treatment delivery system and contain, among other data, information 
about spot position, monitor units (MU) and energy. 
Advances to meet the challenges 
With the capabilities of new combined imaging and delivery machines (MR-LINAC), the photon therapy 
world is about to implement daily adaptive treatment regimens (Beaton et al 2019, Corradini et al 2019, 
Hunt et al 2018) while in PT still rarely more than two or three adaptations are applied throughout the 
whole treatment course (Mohan and Grosshans 2017, Mohan et al 2017). Time-consuming manual step-
wise treatment workflows, the inflexibility of commercial PT equipment (including the treatment 
planning and oncology information software) and the high diversity in the PT landscape currently 
prohibits to move towards daily (real-time) or even online (during beam delivery) 4D adaptive treatment 
approaches. The automation of workflows will play a key element in the further enhancement of 4D 
planning and delivery of PBS-PT. To make adaptive workflows sustainable, also a broader employment 
of hypofractionated treatment regimens might be required (see article on “Efficient Treatment Room 
Utilization”). 
Imaging capabilities at PT facilities have significantly improved over the last years. CT imaging has 
been the standard for many years. New PT facilities are often equipped with in-room or near-room CT 
scanners enabling smooth repeated CT workflows. In the context of daily or online 4D adaptive 
treatments, daily (or continuous during beam delivery) 4D imaging is required. That cannot be achieved 
via CT due to the imaging dose. CBCT and MR imaging might be alternatives in this case.  While CBCT 
has been an established technique in photon treatment rooms for almost two decades, the widespread 
adoption of volumetric image guidance in particle therapy is recent (Landry and Hua 2018). Onboard 
MR guidance for particle therapy is currently not commercially available but is being actively 
investigated. A recent review paper (Oborn et al 2015) predicted the accelerated development of 
hardware and simple prototype systems within a few years and coupled systems integrated with gantries 
in a decade. To achieve online 4D imaging and subsequently (online) 4D adaptive PBS-PT with either 
modality, CBCT or MR, further developments are required. (see articles on “Image Guidance” and 
“Adaptive Therapy”) 
Automatic synthetic CT generation: Neither CBCT nor MR scans are suitable for proton dose 
calculations. The clinical implementation of daily or online 4D adaptive PBS-PT will rely on the 
establishment of automated methods to generate synthetic CTs (sCT) based on CBCT or MR. Especially 
promising in this context are approaches based on deep learning techniques.  
For CBCT deep learning based sCT generation approaches have been investigated (Kida et al 2018). 
However, for 4D applications, only DIR-based sCT generation methods have been investigated (Veiga 
et al 2016, Niepel et al 2018) with minor focus on the automation.  
Also, sCT generation based on MR images has been investigated for MR-based PBS-PT (Maspero et al 
2017, Guerreiro et al 2019). There are no papers yet on 4D MR-based PBS-PT employing deep learning 
sCT generation approaches with a high level of automation. 







































































Automatic image processing: Automation will also play a major role in contouring for 4D adaptive PBS-
PT. Manual delineation on 4DCT is resource intensive due to the high volume of data, which results in 
longer contouring duration and uncertainties in defining the target. A recent review concluded that auto-
contouring for lung tumors is reliable and efficient, producing accurate contours with better consistency 
compared to manual contours (Wong et al 2019). However, manual inputs were still required both before 
and after auto-propagation. 
Automatic quality assurance (QA): With the employment of 4D adaptive PBS-PT treatment regimens 
patient specific QA workflows also must become more efficient. The current clinical practice of 
experimental validation of individual fields will have to be replaced by automated simulations using 
treatment planning steering files or machine log files and a Monte Carlo (MC) code as independent dose 
calculation engine (see article on “Treatment Planning”). Concepts towards effective and efficient 
patient-specific quality assurance for PT have been developed by several groups (Zhu et al 2015, 
Winterhalter et al 2018, Matter et al 2018). 
Concluding remarks 
A paradigm shift from manual stepwise to automatic seamless and flexible treatment approaches is 
required for the clinical implementation of real-time or even online 4D adaptive PBS-PT. 4D imaging 
(also see section on ‘Improving imaging’) for treatment planning, 4D treatment planning, 4D QA and 
4D treatment verification must be integrated into a real-time 4D adaptive PBS-PT treatment loop to 
achieve significant improvements in the treatment of mobile cancer indications. 
 
Considering the relative biological effectiveness of protons 
Harald Paganetti 
Status 
Currently tumor prescription doses and organ at risk constraints in proton therapy are based on a generic 
and constant RBE (relative biological effectiveness) of 1.1 to normalize the physical dose to a photon 
equivalent. Prescription doses are reported as Gy(RBE). The value of 1.1 was chosen in the early days 
of proton therapy based on measured RBE values in-vivo relative to Co60 in the center of the target 
volume at ≥2 Gy per fraction for various endpoints such as skin reaction and LD50. It was chosen 
conservatively to ensure target coverage with prescriptions based on photon experience. Based on an 
analysis of all published cell survival data in vitro fitted with the linear-quadratic dose response curve 
(with parameters a and b), the estimated average RBE is about 1.15 in the center of a typical spread-out 
Bragg peak (SOBP) at 2 Gy(RBE) per fraction (Paganetti, Niemierko et al. 2002, Paganetti 2014). 
Aiming at a conservative RBE for tumor control, this is in line with the clinical use of 1.1 if an average 
RBE is to be applied for the target and if clonogenic cell survival in vitro serves as a surrogate for tumor 
cell kill. For normal tissue the RBE can be substantially higher (Paganetti 2014), which is currently 
neglected in treatment planning. Elevated RBE values can be expected particularly at the end of range 
where the linear energy transfer (LET) is increasing when protons decelerate. 
Our current knowledge on variations in RBE is largely based on measurements of clonogenic cell 
survival in vitro. Figure 7 shows a fit through the majority of published experimental data. Various RBE 
values for endpoints other than cell survival have also been measured in vitro and in vivo but results are 
inconsistent. 











































































Figure 7: Proton RBE for clonogenic cell survival as predicted by an empirical model (McNamara, 
Schuemann et al. 2015). Left: RBE as a function of LETd at 2 Gy for (α/β)x = 2 Gy (solid) and 10 Gy 
(dashed). Middle: RBE as a function of dose for LETd=2.5keV/µm for (α/β)x = 2 Gy (solid) and 10 Gy 
(dashed). Right: RBE as a function of (α/β)x for a photon dose of 2 Gy and LETd values of 2 keV/µm 
(solid) and 10 keV/µm (dashed). The grey areas and projection lines highlight the clinically most relevant 
regions for standard fractionation. (α/β)x refers to the ratio of a and b for the x-ray dose-response curve. 
RBE studies based on patient data are inconclusive due to limited data sets and generally low toxicity 
incidents. There is however increasing concern that proton RBE for normal tissue injuries may be 
underestimated significantly, leading to unexpected toxicities (Haas-Kogan, Indelicato et al. 2018). 
There is anecdotal evidence that toxicities seen with protons might be more severe but not more frequent 
compared to photon therapy. A potential explanation is that patient variability is magnified by RBE 
effects (Paganetti 2017). 
A Task Group report by the AAPM from 2019 concluded (Paganetti, Blakely et al. 2019): 
• The current clinical practice of using a constant RBE for protons should generally be maintained but 
specific clinical scenarios warrant a change in current practice. 
• It is important to acquire clinical data to allow the reconstruction of RBE doses and correlate with 
clinical outcome in both prospective and retrospective studies. 
• There are sites and treatment strategies to be identified where variable RBE might be safely utilized 
for clinical benefit. 
• The proton therapy community needs to assess the potential clinical consequences of delivering 
biologically weighted doses based on LETd and/or RBE and as a function of dose and biological 
endpoints and assess the potential for harm and benefits associated with the clinical implementation 
of variable RBE and dose-weighted LETd models into treatment planning systems. 
• Experiments are needed to improve our current understanding of the relationships among in vitro, in 
vivo and clinical RBE and develop recommendations to minimize the effects of uncertainties 
associated with proton RBE for well-defined tumor types and critical structures. Given the clinical 
practice of multi-modality treatments, RBE experiments using radiation-drug combinations are 
needed as well. 
A retrospective qualitative and quantitative analyses of late-phase lung-density changes (indicative of 
asymptomatic fibrosis) for a small cohort of breast cancer patients irradiated to the chest wall showed 
that late-phase asymptomatic radiographic changes in the lung are associated with a proton RBE 
potentially even exceeding 3.0 (Underwood, Grassberger et al. 2018) for 2 Gy/fraction. In contrast, for 
the same endpoint, an RBE on the order of 1.1 was deduced in a cohort of hypofractionated (SBRT) lung 
cancer patients even though differences in the time course of the inflammatory response after proton 
compared to photon SBRT were seen (Li, Dykstra et al. 2019). A study on rib fractures in breast cancer 
patients indicated elevated RBE values at the end of range similar in magnitude compared to clonogenic 
cell survival data (Wang, McNamara et al. 2020). 








































































Toxicities are a major concern particularly for pediatric patients but it is unclear if RBE variations have 
a clinical impact (Indelicato, Flampouri et al. 2014, Sethi, Giantsoudi et al. 2014). The potential impact 
of LET or RBE on brainstem necrosis in patients has been analyzed (Peeler, Mirkovic et al. 2016, Eulitz, 
Troost et al. 2019). Unfortunately, most studies do not consider the correlation of voxels from the same 
patient as well as the fact that high LET regions are typically in the periphery of the target where high 
doses will also increase the likelihood of toxicities. In fact, when patients were analyzed individually, 
no correlation of elevated RBE in necrotic regions was seen in a cohort of 50 adult patients (Niemierko, 
Schuemann et al. 2019).  
Current and Future Challenges 
While of limited value for establishing RBE values in patients, in vitro studies still offer valuable 
information to our understanding of the basic biological responses to proton and photons radiation. 
Challenges remain on how to standardize measurements to allow inter-institutional comparison and to 
limit the large uncertainties in reported data (Durante, Paganetti et al. 2019). 
There are currently significant uncertainties in proton RBE values, particularly for in vivo endpoints. 
Human tumor responses can be measured in vivo using measurements such as the dose for 50% local 
control of the tumor using human tumor cells implanted in immune-deficient animals but translation into 
the clinic is questionable. As for patient data, it is unlikely that toxicity data from single institutions will 
suffice to define RBE for normal tissue endpoints. Due to the uncertainties in RBE, treatment plan 
optimization based on RBE models is not feasible with clinically acceptable accuracy as patient 
variability is likely in the same order of magnitude as RBE variations and uncertainties. 
Considering typically lower α/β values in healthy tissues, at least for cell survival, as well as lower doses 
than in the target, one might expect larger RBE values for normal tissue. One reason for our difficulty 
to assess RBE effects in critical structures from clinical data is the difference in dose distributions after 
photon and proton irradiations. Most outcome studies are based on normal tissue complication 
probability (NTCP) models that are mainly based on dosimetric indices extracted from dose-volume 
histogram (DVH) data (see articles on “Selection of Patients” and “Outcome Modeling”). As proton dose 
distributions in normal tissue are typically more heterogeneous, estimation of RBE (defined for the same 
level of effect in a homogeneous area of dose) is challenging. 
A value of 1.1 seems appropriate for the tumor if one aims at a conservative value. But RBE depends 
not only on factors such as fractionation and LET, but also the genomic characteristics of human cells. 
An important barrier to assessing the biological effects of proton therapy clinically is the paucity of 
predictive biomarkers (Willers, Allen et al. 2018). Individualized dose prescriptions are desirable, not 
only in proton but also in photon therapy. (see article on “Biomarkers”) 
Advances to meet challenges 
Even though uncertainties in RBE impacts both, tumor control as well as NTCP, one might expect a 
bigger clinical impact on NTCP because 1.1 was chosen conservatively. Nevertheless, moving forward, 
incorporating RBE variations in treatment planning could impact tumor control probability as well. In 
general, the impact is driven by the steepness of the dose-response curve in the region of interest. 
Identifying patients that most benefit from protons (see article on “Selection of patients for proton 
therapy”) should include not only dosimetric but also biological markers identifying individual patients 
with, for example, high tumor RBE. For instance, a subset of human cancers are expected to show defects 
in DNA repair pathways that may influence the RBE (Rostek, Turner et al. 2008, Grosse, Fontana et al. 
2014, Liu, Ghosh et al. 2015). Additional studies on genomically characterized human cancer cell lines 
and normal human tissue would be valuable.  










































































One has to keep potential RBE variations amongst patients in mind when comparing doses in clinical 
trials or when analyzing toxicities and tumor recurrences. With a continued use of a constant RBE the 
interpretation of outcome data might be misleading when tissue- and spatially variant RBE variations 
are neglected (Paganetti 2017, Chen, Grassberger et al. 2018). 
In order to move towards a true understanding of RBE values in patients, the analysis of outcome data 
using blood and imaging biomarkers is urgently needed (see article on “Biomarkers”). Particularly for 
healthy tissue, retrospective investigations on toxicity are currently based on limited number of patients. 
Furthermore, dose-response relationships should ideally not be solely analyzed based on organ contours 
but on sub-regions or even voxel-based (Palma, Monti et al. 2019). Moving forward, machine-learning 
techniques will be a powerful tool particularly when trying to identify radiosensitive sub-regions in 
organs utilizing the different dose distributions from protons and photons. 
Ideally, treatment planning systems would incorporate RBE models and optimize based on RBE-
weighted doses. However, as discussed above, our knowledge on mechanisms of normal tissue toxicity 
prevents this for the foreseeable future. Ongoing efforts on implementing models into treatment planning 
programs will help estimate potential effects but such models may not be ready for plan optimization.   
IMPT allows the delivery of inhomogeneous dose distributions for each field causing plan degeneracy  
(Lomax 1999). As a consequence, LET distributions can be influenced in IMPT without significantly 
altering the dose constraints in treatment planning, i.e. dosimetrically equivalent plans can show 
differences in LET distributions (Grassberger, Trofimov et al. 2011, Fager, Toma-Dasu et al. 2015, 
Unkelbach and Paganetti 2018). This can be utilized to decrease the efficacy of proton therapy in certain 
regions of normal tissue, allowing biological dose optimization despite uncertainties in RBE values 
(Unkelbach, Botas et al. 2016). Translating this method into clinical routine will be beneficial for many 
patients. The method is largely insensitive to organ and patient specific variations in RBE but, depending 
on the number of fields, works better for normal tissue than for tumors. 
Concluding remarks 
A constant RBE of 1.1 is an appropriate average value for ensuring tumor control. However, particularly 
at the end of range, RBE values are likely higher, potentially affecting normal tissue toxicities. 
Understanding the difference between photon and proton radiation is now of critical importance because 
treatment planning vendors may start to prematurely offer RBE based treatment planning using models 
based clonogenic cell survival data. 
Whilst useful in modeling and for understanding biological mechanisms, neither in vitro nor animal 
experiments will ultimately resolve the issue of how proton RBE should be incorporated clinically for 
personalized treatment planning. The paucity of clinical evidence indicates that RBE variations maybe 
on the same order than variability in patient radiosensitivity. Retrospective and prospective outcome 
studies have to be prioritized. Proton therapy, with its typically more heterogeneous dose distributions 
compared to photon therapy allows better understanding of volume effects in organs at risk (see article 
on “Outcome Modeling”). Analyzing proton patients will thus also benefit outcome modeling for 
conventional treatments. 
In the meantime, LET based optimization techniques should be implemented clinically as they allow 
judging treatment plans based on dosimetric indices while likely reducing the risk for normal tissue 
toxicities. 
 
Part 3: Improving imaging 











































































Advances in imaging for proton treatment planning 
Christian Richter and Patrick Wohlfahrt 
Status 
X-ray computed tomography (CT) is the undisputed primary imaging modality for proton treatment 
planning, specifically for dose calculation. The basic methodology, namely the conversion of CT 
numbers (CTN) derived from a native single-energy CT (SECT) into a quantity relevant for dose 
calculation (usually the stopping-power ratio, SPR) using a heuristic conversion function (Hounsfield 
look-up table, HLUT), has kept unchanged since the pioneering years of clinical proton therapy. 
Nevertheless, in the past decade relevant improvements in CT imaging were introduced (Wohlfahrt and 
Richter 2020). With iterative reconstruction techniques image noise can be clearly reduced, bearing 
substantial potential for dose reduction. Still, they have not yet found their way in broad clinical use. In 
contrast, automated tube current adaptation during acquisition with respect to the patients’ anatomy is 
widely applied, allowing for a constant noise level over different CT slices and effectively reducing 
imaging dose.  
For improved tumor delineation and staging, complementing contrast-enhanced SECT scans and/or 
positron emission tomography (PET) and magnetic resonance imaging (MRI) are utilized depending on 
the target. As PET or MRI scans are often performed at different scanners and time points, additional 
challenges arise from deviations in patient positioning and the required involvement of image 
registrations. 
Notably, CT imaging and CTN-to-SPR conversion protocols vary largely between centers as well as the 
acquisition and processing of multimodal imaging, introducing severe inter-center variations in dose 
calculation and delineation (Vinod et al 2016a), potentially interfering with the outcome of multi-centric 
clinical trials. 
Current and future challenges 
The reduction of the uncertainty in CT-based SPR and range prediction is a major challenge. The 
limitations of the HLUT approach are the dominant cause of the nominal range uncertainty in treatment 
planning which has remained practically unchanged over decades with 3-3.5% of the absolute range 
(Taasti et al 2018). This is not unfounded, as a recent inter-center comparison, conducted within the 
European Particle Therapy Network, revealed a 2.6%-2.9% variation in range prediction. For other 
imaging modalities, like MRI or cone-beam CT, the range prediction accuracy is inferior to CT, currently 
prohibiting their application for proton treatment planning. Still, with appropriate and required 
improvements, they could potentially be used in adaptive workflows, as long as the uncertainty in range 
prediction is smaller than the detected treatment deviation. 
An overarching challenge in pre-treatment imaging is an appropriate tissue differentiation, being 
important not only for accurate SPR assignment, but also for tumor and organ-at-risk segmentation in 
general. 
We define the following long-term goals, which would lead to relevant improvements: 
-  Range prediction accuracy ≤1% with CT-based imaging 
- Automated tissue differentiation for segmentation and appropriate SPR assignment for non-CT 
imaging 








































































- General improvements in target and organ-at-risk delineation, e.g. using different, purpose-tailored 
image contrasts and artifact reduction techniques 
- Reduction of inter-center variability in SPR prediction and delineation. 
Advances in pre-treatment imaging to meet challenges 
The clinical availability of dual-energy CT (DECT) scanners in radiology has enabled various 
applications to improve the diagnostic efficiency and efficacy within the last 15 years and is now often 
common practice (Agrawal et al 2014). Despite the large research interest in radiation oncology, the first 
use of DECT for routine proton treatment planning was realized in 2015. Its widespread clinical 
implementation will become apparent in the near future with increasing evidence for its benefits 
especially for proton therapy. 
Due to a better material differentiation with DECT and thus incorporation of intra- and inter-patient 
tissue variations, current intrinsic limitations in CT-based stopping-power prediction using an HLUT 
can be clearly diminished. A relevant reduction of the current range uncertainty of 3-4% to below 2% 
has already been proven to be clinically feasible with DECT-based direct SPR prediction (Wohlfahrt and 
Richter 2020) and might be further decreased by improvements in post-processing algorithms (beam 
hardening and scatter correction, patient size estimation, image smoothing and de-noising). Efforts of 
CT vendors to provide SPR datasets as input for dose calculation together with dedicated calibration of 
their CT systems would clearly facilitate the clinical workflow and contribute to a desirable 
standardization to reduce the current large inter-center variations.  
Furthermore, the generation of virtual monoenergetic images after CT acquisition provides different 
image contrasts - low energy (40-60keV) for increased soft tissue contrast or high energy (120-200keV) 
to reduce metal artifacts. Separating the distribution of contrast agents in images can further contribute 
to a better tumor visibility and might even serve as a measure of organ functions or tumor metabolism 
(functional imaging). The assessment of the optimal application and resulting potential benefit of such 
additional information for target and organ-at-risk segmentation is currently limited and needs to be 
comprehensively addressed in future studies.  
Nowadays, several DECT acquisition techniques exist (dual-source, dual-layer, fast-voltage switching, 
dual-spiral). Each of them offers specific benefits and also disadvantages in terms of energy separation, 
tube current modulation, field of view as well as spatial and temporal differences in projections. Hence, 
no DECT device for general-purpose application in radiation oncology currently exists and a 
compromise has to be made based on the respective objective and individual requirements (Wohlfahrt 
and Richter 2020; van Elmpt et al 2016). 
Photon-counting CT systems, the expected next-generation CT technology with energy-resolving 
detectors, will potentially overcome the mentioned technical limitations of current DECT techniques due 
to a spectral separation in several energy bins after CT acquisition while maintaining full temporal 
resolution. Hence, the accurate direct SPR prediction methods developed for DECT will also be 
unconditionally applicable for body regions with motion-induced anatomical changes. Moreover, 
projection-based corrections for beam hardening and scattering are thus unconditionally feasible. The 
availability of multi-dimensional attenuation information (diverse combination of energy bins) seems 
promising to improve material differentiation, which potentially leads to a higher tissue contrast for 
tumor and organ segmentation and differentiation of multiple contrast agents. In initial proof-of-concept 
studies, first prototypes have shown a comparable or slightly better accuracy in SPR prediction and 
material classification than DECT. Further improvements in spectral de-noising techniques might also 
reduce the current restrictions in the selection of an appropriate number of energy bins due to 
unacceptably high image noise. Photon-counting CT can thus become an emerging alternative to DECT 









































































in radiation oncology (Willemink et al 2018). 
Range probing, comparing measured and expected depth dose after patient transmission, is a promising 
tool to verify CT-based range prediction and eventually adapt the CTN-to-SPR conversion (Parodi 
2020). Its widespread clinical application would require a smooth integration in proton therapy systems.  
The acquisition of three-dimensional stopping-power information using proton CT has been an active 
focus in research for decades, resulting in first experimental prototypes, which are still in an early stage 
of development. With the ongoing improvements and clinical implementations of dual-energy CT or 
photon-counting CT, the potential additional  gain in SPR accuracy from proton CT becomes smaller 
and might be not even clinically relevant at some point. Proton CT would also come with considerable 
additional costs, would only be applicable for a limited number of body regions due to the current 
restriction in maximal proton energy (roughly 230 MeV) at most centers, and would reduce the number 
of patient treatments caused by long acquisition times (several minutes) in the proton treatment room 
(Johnson 2018). A better scatter prediction already clearly improved the proton CT image quality, but 
physical constraints limit further improvements in spatial resolution at high-density material gradients 
and resulting ring and streak artifacts (Parodi 2020). Potential use cases could be patients with metal 
implants close to the treatment volume (Johnson 2018). However, the continuous improvement of 
artifact reduction techniques in (multi-energy) x-ray CT could be the clinically sufficient and more cost-
effective alternative. 
Figure 8: Potential advances in imaging for proton 
treatment planning, starting from the current 
situation (bottom). They can be grouped in two 
tracks – improvements for range prediction accuracy 
and improvements for tissue segmentation. The 
proposed periods correspond to the broad clinical 
application of the respective techniques. (autoSEG= 
auto segmentation). 
MRI offers a broad variety of acquisition modes to 
differentiate soft tissues and to assess their 
functional behavior. Combining multi-modality 
imaging including MRI has proven to reduce intra- 
and inter-observer variability in delineation (Vinod 
et al. 2016b). The robustness and accuracy of MRI-
based material assignment (e.g. synthetic CT 
generation) for SPR prediction could potentially be 
improved by using DECT or even proton CT instead 
of SECT as input. Improvements in geometrical 
accuracy, motion detection and management as well 
as accuracy and precision of quantitative MRI are 
ongoing research challenges (Das et al. 2019). 
Hence, synchronized multi-modality imaging in 
treatment position is worth aspiring to combine the 
respective advantages of each technique, decrease 
registration errors and maximize the patient-specific 
tissue information available for treatment planning.  
Moreover, the technological achievements in 
imaging enable an accurate and precise experimental determination of the mean excitation energy in 









































































biological tissue samples and patients by combining DECT and range probing or proton CT, respectively. 
A combination of MRI and DECT or even photon-counting CT can facilitate an even better in-vivo 
material differentiation and characterization compared to a single-modality approach. 
Concluding remarks  
The field of pre-treatment imaging has gained substantial translational research interest. DECT, offering 
substantial reduction of range uncertainty, is currently at the critical cornerstone of broad clinical 
implementation. In terms of range accuracy, it will set the benchmark for other techniques. Therefore, 
photon-counting CT will potentially bring benefits for segmentation from tailored image contrasts and 
enabling direct SPR prediction, as introduced with DECT, for a broader patient population (motion-
influenced regions) rather than further decreasing range uncertainties substantially. The investigation 
and tailoring of photon-counting CT for proton therapy requirements will thus be an exciting field of 
translational research. For proton therapy applications of all imaging modalities, quantitative imaging in 
clinical realistic scenarios is key and should be considered in calibration and validation studies, e.g. using 
phantom setups covering different clinical scenarios. 
In summary, we are confident, that not one single imaging modality will fulfill the broad spectrum of 
radio-oncological needs. Hence, research efforts should focus on finding the best multi-modal synergies. 
Bringing together imaging and radiation oncology expertise is thus becoming more and more crucial. 
Figure 8 outlines potential advancements in the next few years. 
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Image guidance 
Bas W Raaymakers and Antje C Knopf 
Image guided Radiotherapy for improved position verification 
In modern radiotherapy, both photon and proton therapy, there is a huge need for imaging; we will argue 
that the roadmap for image guidance in proton therapy is heavily affected by the experiences in the 
photon therapy. Image guided radiotherapy (IGRT) is a long standing research and clinical innovation 
area (Verellen et al., 2007). Imaging in radiotherapy has mainly been developed for improving position 
verification, that is, to validate the anatomy on the treatment couch relative to the anatomy during 
treatment planning. The more precise position verification during fractionated radiotherapy treatments, 
the more conformal dose distributions to the target can be enabled, sparing surrounding healthy tissue 
from unwanted dose. 
A host of imaging modalities is being applied while also surrogates for imaging the target, e.g. using 
nearby bony anatomy or fiducial markers (Nederveen et al, 2003), are (and can) be used. Most prominent 
in IGRT is the development and clinical introduction of cone-beam CT (CBCT) acquired from a patient 
in the actual treatment position (Jaffray et al., 1999). Such volumetric data enables much more precise 
target identification and with that, patient positioning and is currently in widespread clinical use (Qin et 
al., 2015).  
Recently, in the photon therapy arena, integrated MRI radiotherapy systems were clinically introduced 










































































(Mutic and Dempsey, 2014; Raaymakers et al., 2017). These systems enable MR imaging of patients in 
the actual treatment position, providing unrivalled, volumetric, soft-tissue contrast data for position 
verification. If desired, this can be continued during dose delivery for continuous patient monitoring. 
Imaging in Radiotherapy for treatment adaptation 
The drive for improved imaging during radiotherapy originates from the need for better position 
verification and has led to daily, volumetric data of the patient from the treatment table. The advent of 
daily volumetric imaging also led to adaptive radiotherapy (ART; see also article on “Adaptive 
Therapy”), as by using the daily data the treatment margins can be re-evaluated (Yan et al., 1997). But 
also, it enables generation of a new treatment plan to account for anatomical changes, e.g. Marchant et 
al. (2018), instead of trying to re-position the patient according to the pre-treatment planning. Also for 
such daily treatment adaptation, the hybrid MRI radiotherapy systems will raise the quality of images 
for clinical decision making on the necessity of adapting. And with their capability to also provide 
repeated MRI data during dose delivery will drive towards intra-fraction plan adaptation and ultimately 
real-time adaptive radiotherapy (Kontaxis et al, 2015). Currently, online, or more specifically daily, MRI 
based adaptation is an accepted clinical reality (Henke et al., 2018).  
Also, recently a new artificial intelligence driven eco-system for adaptive photon beam therapy is 
commercially launched for clinical introduction (www.varian.com/ethos). This workflow uses CBCT as 
an input, so it lacks the soft-tissue contrast of MRI, but it provides an integrated, fast, adaptive workflow, 
which enables 15 minutes full adaptive radiotherapy treatment fractions for certain tumor sites. 
Which imaging modality will be most suitable for which tumor site, the frequency of adaptation and the 
delivery on the promise that this will lead to more hypo-fractionation needs to be established from 
clinical experience. The desire for improved position verification and more frequent treatment adaptation 
will jointly require better, and more frequent, imaging.  
Roadmap for image guidance in Proton therapy 
The introduction of the imaging and adaptive innovations has mainly taken place in the photon therapy 
clinic, widespread adoption in proton therapy is lagging for these developments (Lomax, 2018). For 
proton therapy both position verification and treatment adaptation are very relevant for improving 
treatment accuracy. IGRT developments from photon beam therapy are being translated to proton 
therapy, e.g. CBCT guidance is being used more and more frequently in proton therapy (Landry and 
Hua, 2018). In essence the roadmap for imaging in proton therapy, where it concerns anatomical imaging 
for position verification and for adaptation, is similar to that of photon therapy. A nuance is that proton 
therapy is considered high-end radiotherapy, both due to its ability to stop the treatment beam posteriorly 
of the tumor to spare the surrounding tissues and due to its costs. To live up to this expectation, imaging 
in proton therapy should be at least of similar quality as the state-of-the-art imaging used in photon beam 
therapy. This implies that the roadmap should aim to obtain real-time, volumetric, high soft-tissue 
contrast imaging to enable position verification, dose reconstruction and treatment adaptation as MRI 
provides for photon beam therapy. 
An additional requirement for imaging in proton therapy is to verify not only the geometrical location of 
the target, but also the proton beam range in the patient (Knopf and Lomax, 2013). Proton radiography 
(Hammi et al., 2018), PET imaging (Parodi et al., 2007) and prompt gamma imaging (Hueso-González 
et al., 2016) are being explored for treatment verification (see also article on “In vivo range verification”). 
Thus, patient imaging during treatment initialization, when the patient is on the treatment table, should 
yield both the anatomical and stopping power data (see also article on “Advances in imaging”). For 
proton therapy both topics are active fields of research (Mackay et al., 2018; Poludniowski et al., 2015). 








































































Alternatively, these imaging data can be used for plan adaptation (see also articles on “Adaptive 
Therapy” and “Treatment planning”). By combining the data, the stopping powers of the various tissues 
in the anatomy can be determined, while all relevant structures for (re-)planning can be identified on the 
anatomical data. Once this is done, the challenge of re-planning is very similar as for photon beam 
therapy, of course with the difference being a proton therapy treatment planning system, for instance by 
daily CBCT based re-planning. For proton therapy, daily CBCT has recently become a clinical reality 
while in-vivo range determination by prompt gamma imaging is awaiting wider clinical employment 
and investigations. So daily CBCT based plan adaptation is something that can be explored currently. 
However, to match the state-of-the-art image quality in photon beam radiotherapy, MRI for anatomical 
imaging should be on the roadmap. 
MRI guided proton radiotherapy 
In MRI guided proton therapy, the need for stopping power data is still equally much needed as with any 
other anatomical image guided modality. If the stopping power data is coupled to the MRI, the repeated, 
ultimately real-time, anatomical data can be used to track the entire anatomy during beam delivery. 
Actually, for proton therapy, with its sharp dose fall off around the Bragg peak, this might be even more 
relevant than for photon beam therapy. MRI guidance in the context of proton therapy has been proposed 
(Raaymakers et al., 2008) and is being explored experimentally (Schellhammer et al., 2018) and in silico 
(Oborn et al., 2017). This is not near clinical reality, still, as these developments to realize real-time 
adaptive MRI guided dose delivery in photon beam therapy are advancing, this should be on the roadmap 
for proton therapy too. 
Concluding remarks 
On-line adaptive radiotherapy is a new clinical reality in the photon radiotherapy world. Volumetric 
anatomical imaging in treatment position as well as a transition to more seamless, automatic workflows 
enables the clinical deployment of online adaptation. For proton therapy to keep up with this reality, the 
road map should include in-vivo range determination by prompt gamma imaging and volumetric 
anatomical imaging of the patient in treatment position on the treatment table. CBCT is a good starting 
point for improving position verification and daily plan adaptation. 
MRI should be on the roadmap as it provides unequalled anatomical imaging for position verification 
but also anatomical tracking of both target and all surrounding structures. These features will drive a 
paradigm shift in photon beam radiotherapy towards online, and ultimately real-time, adaptive 
radiotherapy, something that will also affect the expectation of proton therapy. A starting point for using 
MRI in proton therapy is to include more MRI in the preparatory phase of treatment planning to 
investigate the coupling of range imaging and MRI. 
Conflict of interest 
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Part 4: Improving patient selection 
 
Model-based selection of patients for proton therapy 
Johannes A. Langendijk and Stefan Both 
Status 









































































Beginning 2018, proton therapy (PT) has been clinically introduced in the Netherlands. In 2015, the 
Royal Netherlands Academy of Arts and Sciences (KNAW) concluded that an RCT (randomized 
controlled trial) is not always the most optimal study design for evaluating the benefit of technology and 
that for different types of new applications, different research approaches are required (Langendijk et al 
2018). Alternatively, for the selection of patients for PT, the so-called model-based approach was 
introduced, which has been accepted by the National Health Care Institute (ZiN) (Langendijk et al 2013; 
Widder et al 2016). Consequently, when adult patients are selected according to a model-based selection 
procedure, PT is insured care and will be fully reimbursed.  
Model-based selection is developed to identify patients that may benefit from PT in terms of reducing 
radiation-induced side effects. It relies on three basic principles: 1) the definition of the target volumes 
and fractionation schedules is similar to what would be used when patients are with photons, assuming 
equivalent tumor control; 2) the dose to the most relevant organs-at-risk (OAR) in the proton treatment 
plan should be lower than that obtained with photons (i.e. ∆Dose), and: 3) this ∆Dose should translate 
into an expected decrease in normal tissue complication probabilities (i.e. ∆NTCP). To translate ∆Dose 
into ∆NTCP, NTCP-models are used, i.e. prediction models that describe the relationship between the 
dose distribution in OAR and ` risk on radiation-induced toxicity. 
For each tumor site, the criteria for model-based selection are described in detail in National Indication 
Protocols for PT (NIPP), which contain general eligibility criteria (e.g. curative treatment), a detailed 
description of the NTCP-models that can be used for model-based selection as well as the ∆NTCP-
thresholds to determine if patients qualify for PT. To assess ∆NTCP, an in-silico plan comparison is 
performed comparing the best dose distribution with photons with the best dose distribution with protons. 
Based on these dose distributions, NTCP-profiles for photons and protons and subsequent ∆NTCP are 
produced to assess if the criteria are met (Figure 9). 
For selection of head and neck cancer, three NTCP-models are used (moderate-to-severe patient-rated 
xerostomia, physician-rated dysphagia grade ≥ 2 and tube feeding dependence). For breast cancer 
patients, an NTCP-model for acute coronary events derived from the Darby model is used (Darby et al 
2013). 
Current and future challenges 
Model-based selection requires high quality NTCP-models, preferably validated in independent datasets 
to test their generalizability of these NTCP-models (Langendijk et al 2018).  
However, for many tumor sites, the numbers of NTCP-models that meet these criteria is limited or are 
currently not available. E.g., the literature review on NTCP-models in low grade glioma patients did not 
reveal any NTCP-model that could be used for model-based selection. So far, these tumors, selection 
strategies should be applied. In the case of low grade glioma, selection is currently based on identifying 
patients with the most favorable prognosis (i.e., 5-years overall survival > 50%) who are at risk for long-
term neurocognitive decline.  Second, virtually all NTCP-models published so far are based on photon-
based radiation techniques. However, NTCP-models can be affected by changes in the irradiation 
technique. Therefore, it is paramount to continuously update and validate these NTCP-models in 
subsequent patient cohorts treated with new techniques. The challenge here is to create an infrastructure 
support for prospective collection of high quality data, allowing for development and validation of 
multivariable NTCP-models for comprehensive sets of radiation-induced toxicities. 
Another important challenge is related to the clinical implementation. Model-based selection as part of 
routine clinical practice is completely new, relatively complex and resource intensive, especially if 
patients are referred from other centers. In head and neck cancer, approximately 30-40% qualifies for 
PT based on the plan comparison, while in breast cancer this is only 5-10%. Performing plan 









































































comparisons in all these patients is logistically not feasible. Therefore, tools to select patients in which 
a plan comparison is indicated are desperately needed.  
Figure 9: Schematic overview of model-based selection 
procedure 
Advances in Science and Technology to Meet Challenges 
Along with the introduction of PT in the Netherlands, a 
nationwide PT research infrastructure (ProTRAIT) is 
currently under construction to support prospective data 
collection of all patients treated with PT. ProTRAIT aims to 
setup PT registries developing tools for radiotherapy that will 
enable an unprecedented combination of both DICOM-RT 
and clinical/follow up data for integrated analysis. More 
specifically, ProTRAIT: 1) defined tumor-specific registries 
for patient groups that are with PT; 2) setup an IT 
infrastructure supporting the model-based approach on a 
national scale by harmonizing data acquisition (clinical, 
DICOM RT); 3) makes data FAIR (Findable, Accessible, 
Interoperable and Reusable) and links data from different 
sources and centers; 4) develops an IT infrastructure that 
supports fast development, update and external validation of 
NTCP models, and: 5) deploys an IT infrastructure to support 
quality assurance in radiotherapy for clinical trials. This 
infrastructure will also be used for collecting data from photon-treated patients for the development and 
validation of NTCP-models. The ProTRAIT-project will be completed in 2021. This approach will be 
further extended on a European scale by the European Proton Therapy Network (EPTN). 
To enhance further adoption of the model-based approach, clinical workflows need to be simplified and 
automated whenever possible. First, heterogeneity across centers in contouring OAR may jeopardize fair 
plan comparisons between photon and proton plans even when international guidelines are available 
(Brouwer et al 2015). Automated contouring using deep learning techniques derived from artificial 
intelligence (AI) has emerged useful to improve performance resulting in smaller dose differences 
compared to manual contouring and marked reductions of delineation times (van Dijk et al 2019). AI 
solutions for automated photon-based treatment planning are currently developed and clinically 
deployed, holding the promise to significantly reduce treatment planning time while eliminating large 
variations in treatment planning performance across centers, as was recently shown in a Dutch 
benchmark study using predefined regions of interest in one patient (Verbakel et al 2019). Similar 
automated planning tools are under development for PT, however this is a more challenging task 
especially when combined with robust optimization (Kierkels et al. 2019). 
To reduce the number of unnecessary plan comparisons, attempts are made to use knowledge-based 
planning solutions (see article on “Treatment Planning”), treatment planning based on prioritizing 
prescription goals or AI, to improve the accuracy of identifying patients who will qualify or not for PT 
prior to a plan comparison in different phases of the preparation workflow (Delaney et al 2017; Wilkens 
et al 2007). As validated NTCP models become available for various treatment sites and combined NTCP 
profiles start to be used, a transition from NTCP evaluation to NTCP evaluation and optimization 
becomes more feasible. This may further improve efficiency of clinical workflows. 
Concluding Remarks 









































































In the Netherlands, patients are selected for PT using a model-based approach provided that PT is 
intended to reduce radiation-induced side effects with similar loco-regional control. The main challenge 
is to develop and validate multivariable NTCP-models to enrich ∆NTCP-profiles that can be used for 
patient selection for both photons and protons. To this purpose, a nationwide IT research infrastructure 
is created (ProTRAIT). In addition, clinical workflows should be optimized and automated to facilitate 
logistic hurdles in patient selection and referral.  
 
Outcome Modeling for Proton Therapy 
Harald Paganetti 
Status 
Both tumor control probability (TCP) as well as normal tissue complication probability (NTCP) models 
are constantly being refined. As normal tissue sparing is one of the main dosimetric advantages of proton 
therapy, it will likely not be tumor control but rather normal tissue complication differences compared 
to photon therapy that will determine its benefits. Several retrospective and prospective studies have 
identified areas where proton therapy does indeed make a significant clinical impact and reduces 
toxicities but there are also studies where an advantage was not seen. Independent of the delivery method, 
proton therapy reduces the integral dose (total energy deposited in the patient) by a factor of 2-3 
compared to photon techniques (Lomax, Bortfeld et al. 1999). While this reduces the overall dose to 
healthy tissue, it may not translate into a toxicity advantage depending on the dose-limiting endpoints 
and how the dose is distributed. 
Models based on parameters deduced from clinical studies are often used to predict clinical outcome 
(Semenenko and Li 2008). For instance in lung, single parameters are extracted from DVHs such as V20 
and mean lung dose to predict radiation pneumonitis in photon therapy (Fay, Tan et al. 2005, Marks, 
Bentzen et al. 2010). However, dose volume parameters deduced from photon treatments might not apply 
to proton treatments with more inhomogeneous dose distributions (Tucker, Xu et al. 2019). For instance, 
dose to the lower parts of the lung is more predictive of radiation pneumonitis than dose to the upper 
lobes (Seppenwoolde, De Jaeger et al. 2004, Hope, Lindsay et al. 2006). 
Proton therapy outcome relative to photon therapy is also affected by RBE considerations (see article on 
“Relative biological effectiveness”). The current RBE formalism assumes that normal tissue 
complication probability estimates for proton therapy can be based on scaled photon doses in each CT 
voxel. There is increasing concern that the RBE for normal tissue injuries may be underestimated, 
leading not only to more but to more severe toxicities than expected from analyzing dosimetric indices 
(Haas-Kogan, Indelicato et al. 2018). Toxicities in proton therapy could be more affected by inter-patient 
variations leading to a wider distribution of the severity compared to photon radiation (Paganetti 2017), 
which would also impede comparisons between cohorts. Predicting in vivo normal tissue responses after 
radiotherapy using in vitro cellular biomarkers and radiosensitivities assumes a direct correlation of 
toxicity with radiation induced DNA damage, neglecting, for instance, the involvement of cytokine-
mediated multicellular interactions in radiation response (Stone, Coleman et al. 2003). As discussed in 
the roadmap article on Systemic effects in Proton Therapy, the integral dose may even influence 
toxicities via impacting immune response. 
Current and Future Challenges 
Most outcome studies apply NTCP models that are based on dosimetric indices extracted from DVH 
data. Even more simplistic and thus complicating IMRT/IMPT comparison, the majority of current 
approaches for modeling of radiation dose-response rely on single parameters such as mean dose or 










































































generalized effective uniform dose to an organ-at-risk represented by a single segmented (contoured) 
region-of-interest (Yorke 2001, Troeller, Yan et al. 2015). Data suggest that such NTCP models might 
fail to discriminate even at the level of physical dose whether an individual proton plan is effectively 
ranked superior to a comparison photon plan (Chaikh, Calugaru et al. 2018, Kobashi, Prayongrat et al. 
2018).  
In addition, non-local effects are complicating comparisons: for instance parotid tissue is treated for 
dose-constraint purposes as having uniform RBE, and thus even tissue radiosensitivity across the organ. 
Irradiation of the rat parotids with a proton beam showed that tolerance of the parotids to irradiation of 
a focal subvolume “shower” (van Luijk, Pringle et al. 2015) is reduced by a sub-tolerance dose 
administered to a larger, surrounding volume “bath” (van Luijk, Faber et al. 2009). There might even be 
fundamental differences in normal tissue toxicities between proton and photon radiation due to not only 
the differences in the distribution of dose, which could interact with varying sub-region sensitivity across 
a larger organ, but also due to not well understood variations in RBE for normal tissue toxicities. 
The questions of photon-based outcome modeling and RBE need to be considered also for model-based 
trial concepts, where a threshold restricts the cohort to theoretically favorable subpopulations (see article 
on “Model based selection”). Toxicities in head and neck cancer have been used as examples for model-
based trial approaches in proton therapy (Langendijk, Lambin et al. 2013) but photon-based NTCP 
models can be insufficient for individual patient plan selection (Blanchard, Wong et al. 2016). 
Advances to meet challenges 
Research is ongoing into defining more relevant dosimetric parameters that go beyond mean doses or 
even DVHs. Voxel-based approaches aim at exploring local dose differences associated with radiation 
toxicities. A voxel-based analysis of dose distributions can thus identify sensitive areas in organs 
independent from drawn contours (Han, Lakshminarayanan et al. 2019, Palma, Monti et al. 2019, Monti, 
Paganelli et al. 2020, Palma, Monti et al. 2020). Figure 10 shows an example illustrating where patients 
with radiation-induced lung damage received a significantly greater dose in parenchymal regions 
although overall low doses were delivered. 
Fig. 10: Left: Significance map (–log p) of BED differences between IMRT and PSPT patients (spared 
regions), Right: significance map (–log p) of BED differences between patients who developed radiation 
pneumonitis and who did not (sensitive regions) (adapted from (Palma, Monti et al. 2019)). 
Refinements of outcome models based on these concepts benefit from data deduced from 
inhomogeneous dose distributions such as delivered in proton therapy. This will lead to a better 
understanding of the mechanisms of normal tissue toxicities which will also improve conventional 
photon therapy. Furthermore, this will increase our understanding for which patient cohorts and 
treatment sites the advanced dose shaping capabilities of protons can be utilized towards a true outcome 










































































While these approaches will improve our understanding of toxicities, outcome models relying on dose 
alone are unlikely to effectively predict toxicities (Rancati, Fiorino et al. 2011). In addition to dose 
distributions, the use of blood and imaging biomarkers to quantify radiation injuries can be incorporated 
to inform predictive models, e.g. by leveraging deep learning methods to incorporate biomarkers and 
other confounding factors into a voxel-based dosimetric analysis. To consider the multidimensional 
nature of NTCP predictions, multivariable logistic regression modeling frameworks have combined 
dose-volume metrices with other patient- or disease-based prognostic factors using data-driven modeling 
to improve outcome prediction (El Naqa, Bradley et al. 2006, Lee, Chao et al. 2014, El Naqa, Kerns et 
al. 2017). Risk factors can be included directly as features in data-driven approaches (Ibragimov, Toesca 
et al. 2019, Ibragimov, Toesca et al. 2020). Such approaches are likely more promising than efforts to 
base outcome modeling on mechanistic input parameters (Rutkowska, Baker et al. 2010).  
Concluding remarks 
This article did focus on NTCP because this might be more relevant and specific to proton therapy as 
long as prescription doses in proton therapy are identical to those in photon therapy (except for RBE 
correction). However, moving forward, both hypofractionation and re-irradiation will increasingly being 
used in proton therapy. This will cause proton specific aspects of TCP modeling to become more 
important. Note also that with re-irradiation becoming more common (a treatment where lower integral 
dose is particularly important), NTCP models need to be extended to scenarios in which multiple targets 
receive dose, or normal tissues are re-irradiated due to new lesions in the same organ. 
Outcome modeling approaches for normal tissue toxicities can be divided into three classes (and 
combinations of them). One is mechanistic effect modeling, which is currently not feasible with 
clinically relevant accuracy. The second type are phenomenological analytical models based on clinical 
data, which are currently standard for most studies. These have now evolved by incorporating 
confounding factors and imaging biomarkers. The third approach are machine learning concepts which 
will play a bigger role to either complement our current outcome formalisms or even replace them 
altogether. Voxel-based dosimetric analysis as well as the incorporation of biomarkers will make this 
transition likely. These efforts will of course impact both photon and proton outcome modeling. 
However, proton therapy will play a large role in research towards novel modeling approaches as the 
more inhomogeneous dose distributions and their variety will be advantageous for refining outcome 
models based on a better understanding of intra-organ sensitivity. 
The aim will not be to develop proton-specific NTCP models but to challenge the current NTCP 
modeling concepts that are mainly based on two-dimensional dosimetric parameters and pre-defined 
structures and volumes of interest. 
 
Biomarkers in Proton Therapy 
David R. Grosshans, Simona F. Shaitelman and Gabriel O. Sawakuchi 
Status  
Technological advancements in radiation therapy have improved our ability to target and eradicate gross 
disease. We have also gained an increased appreciation for the potential side effects of radiation therapy, 
quantified the magnitude of such effects, and documented their negative influence on quality of life for 
cancer survivors. However, our ability to predict whether tumors will respond to treatment or patients 
will suffer from treatment-induced toxic effects is limited largely to classical dose‒response 









































































relationships, and little is known about the susceptibility of individual patients and their tumors. 
Efforts to improve tumor control have included various dose escalation or fractionation strategies, as 
well as sequential or concurrent treatment with chemotherapies or other antineoplastic agents. Such 
strategies have been successful in increasing tumor control rates, albeit at the cost of additional toxicity; 
however, we remain unable to predict either tumor response or radiation-induced toxic effects for 
individual patients. In part, this is because technological advances in radiation delivery have been driven 
by anatomic targeting based solely on physical factors. However, the intrinsic physical properties of how 
radiation interacts with cells and tumor tissue set a theoretical limit on the anatomic targeting of 
radiation. Currently, we know that radiation response is affected by various biological factors including 
genomics (Scott et al., 2017), the microbiome (Reis Ferreira et al., 2019) of tumor and normal tissues, 
the immune system (Twyman-Saint Victor et al., 2015), and the tumor microenvironment (Vaupel, 
2004). Finding predictive features within these biological factors will add another dimension for 
predicting response or toxicity.  
The term “biomarker” refers to a measurable and quantifiable indicator of response. It stands to reason 
that maximizing cure rates and reducing toxicity will require biomarkers based on unique biological 
factors to predict tumor response or treatment-induced toxicity for individual patients, whether treatment 
is with radiation alone or in combination with molecularly targeted therapies. 
An example of the need for biomarkers is highlighted by proton therapy, a prime example of physics-
driven technological advancement in radiation oncology for which biomarkers have not been explored. 
Proton therapy is expensive, and clinical evidence indicating its superiority to modern photon therapy is 
lacking. Therefore, biomarker development is crucial to facilitate the selection of appropriate patients 
for proton therapy and thereby provide high-level clinical evidence supporting its use.  
Current and Future Challenges 
Most biomarker studies related to radiation therapy have focused on identifying predictors of tumor 
response to photon-based therapies (Scott et al., 2017; Yard et al., 2016; Manem et al., 2019). Such 
predictive knowledge would allow stratification of patients into discrete groups based on likely response, 
and would allow treatment intensification or de-intensification or even prospective customization of dose 
and fractionation for individual patients. Although the potential for biomarkers is great, our 
understanding of factors associated with radiation response, even for photons, is limited. However, 
examples are emerging. A prime example of a potentially clinically useful predictive biomarker includes 
the human papillomavirus (HPV) status for patients with head and neck cancers. HPV-associated tumors 
have relatively high cure rates (Ang et al., 2010), and dose de-escalation strategies that lead to less 
radiation-induced toxicity are now being assessed. Other attempts made to predict radiation sensitivity 
include assessing the clonogenic survival or DNA damage response of tumor cells cultured from 
individual patients. However, these approaches are labor-intensive and time-prohibitive for enabling 
rapid changes to clinical care plans.  
Genomic techniques may hold more promise for this purpose (Scott et al., 2017; Yard et al., 2016; 
Manem et al., 2019). Genomic biomarkers use genomic features of tumor or normal tissue samples in an 
attempt to identify patterns indicative of tumor response to radiation or radiation-induced toxicity. Tools 
to identify signatures of response are evolving rapidly and include newer bioinformatics techniques as 
well as the analysis of new publicly available datasets (Scott et al., 2017; Yard et al., 2016; Manem et 
al., 2019).  
In addition to blood or genomic biomarkers, imaging biomarkers may also be of great utility  (Elhalawani 
et al., 2018). Imaging in radiation oncology has historically been used for target delineation, verification 
of positioning, and response assessment. However, functional imaging modalities such as magnetic 








































































resonance imaging may also provide insight into the biology of how tumors (or subsections of tumors) 
and normal tissues of individual patients respond to radiation, which may relate to intrinsic radiation 
sensitivity. Like genomic biomarkers, imaging biomarkers may allow identification of patients who 
might benefit from dose escalation, thereby improving local control.  
With respect to proton therapy, for practical purposes the biological effects of protons and photons have 
been assumed to be relatively similar, with protons on average being 10% more biologically effective 
than photons; thus, a relative biological effect (RBE) value of 1.1 is used to normalize physical dose for 
treatments (see article on “Relative biological effectiveness”). However, at the cellular level, the patterns 
of proton-induced DNA damage differ from those of photons, particularly in areas of high linear energy 
transfer (LET). In studies of cell lines, these differences correlate with decreased clonogenic survival, 
resulting in RBE values approaching 1.8, even in areas proximal to the Bragg peak. More importantly, 
different cancer cell lines of the same histologic type have a large range of RBE values (Liu et al., 2015). 
These differences in response likely arise from intrinsic genomic differences, such as capacity to repair 
clustered DNA damage, that are more likely to be affected by protons (Bright et al., 2019). While in 
most cases such alterations are likely limited to the tumor itself, individual patients with particular 
germline mutations, which also affect normal tissues, must be carefully identified to avoid adverse 
radiation-induced toxic effects that could be induced by protons because of their higher RBE. The 
identification and quantification of predictive biomarkers of tumor and normal tissue response to protons 
would allow practitioners to identify patients whose 
cancer would be best treated with protons (aside from 
favorable dose distributions alone) while reducing 
toxic effects (Figure 11). Other tumors with certain 
forms of DNA repair defects may be equally 
sensitive to photons and protons, and therefore use of 
protons for such tumors would be based on protons’ 
superior dose distribution. On the other hand, tumors 
that are radiation-resistant to photons might be better 
suited for treatment with heavier ions, in which the 
still-higher LET may overcome resistance. Genomic 
approaches seem the most plausible to achieve this 
goal.  
Figure 11: Illustration of a genomic biomarker 
framework to predict tumor response to proton therapy. 
Advances Needed to Meet Challenges  
The primary challenge for all biomarker development is the need for large patient or preclinical datasets, 
with accurate response data coupled with genomic or other relevant information (see article on “Outcome 
Modeling”). Although some datasets are being developed for photon radiation (Scott et al., 2017; Yard 
et al., 2016; Manem et al., 2019), very few are available for proton therapy. Hence, a necessary step will 
be the development of preclinical and clinical datasets of patients treated with proton therapy. From a 
preclinical perspective, cellular response data can be obtained, albeit at high cost. Clinical datasets will 
be even more challenging, given the limited number of clinical proton centers and the general lack of 
banked tumor samples for future study. Successful advancement of proton (or particle) therapy will 
require significant funding and collaboration between numerous investigators. As sample acquisition 
and annotation improve, so will data analysis techniques such as machine learning and artificial 
intelligence, which may even reduce the number of data points required. Another urgent need is 
information for predicting normal tissue toxicity, even for photons. However, investigations of normal 









































































tissue toxicity face greater obstacles, as severe radiation toxicity events are thankfully relatively rare.  
Concluding Remarks  
A perceived challenge for biomarker studies is the prospective analysis of candidate biomarkers. 
However, the advent of proton and particle therapy may eventually necessitate the use of predictive 
biomarkers for selecting patients who will derive meaningful benefit from these modalities. Predictive 
biomarkers are now being used in trials of new anticancer pharmaceutical agents to select patients who 
will respond to those agents, which essentially biases such studies in favor of a successful trial. Future 
biomarkers may allow us to predict tumor and normal tissue responses that in turn may indicate an 
increased biological response to particle therapy, including protons. This, along with refinement of 
delivery technologies, would allow proton therapy to reach its full potential in smaller, more efficient 
trials.  
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Systemic effects of proton therapy 
Harald Paganetti and Clemens Grassberger 
Status 
The lower integral dose and reduced toxicity of proton therapy offers an opportunity to explore clinical 
trials combining proton therapy with intensified systemic therapy and/or dose-escalated radiotherapy. 
Proton chemo-radiotherapy administered concurrently has been shown to be associated with 
significantly reduced acute adverse events that caused unplanned hospitalizations, with similar disease-
free and overall survival (Bauman et al. 2019). While radiation therapy has mostly been combined with 
surgery and/or chemotherapy up to now, the cancer treatment landscape has changed significantly with 
the addition of targeted agents as well as immune-modulating therapies in recent years. Thus, even 
though combinations of radiation and drugs are the standard of care, the field is advancing quickly as 
new drugs and trial results become available. The combination of radiation with biological agents can 
have tumor-directed as well as toxicity-related effects, and interactions can be additive, supra-additive, 
or infra-additive. There is a paucity of clinical data regarding differences in proton vs. photon outcomes 
in the setting of targeted therapy. However, there is emerging data that differences in signaling pathways 
with proton therapy may help to overcome radioresistance (Konings et al. 2020). 
For instance, radiation therapy has both immune-stimulatory and immune-suppressive effects. The 
interaction of radiation with the immune system is complex and often difficult to interpret as radiation 
has detrimental effects not only on tumor infiltrating lymphocytes, lymphatic vessels and nodes, but also 
on circulating lymphocytes in the blood (Kaur and Asea, 2012). In addition to baseline lymphopenia and 
other markers of inflammatory status in solid tumor patients, radiation-induced lymphopenia (RIL) 
develops in up to ~70% of radiation therapy patients (Ellsworth, 2018; Yovino et al., 2013; Wild et al., 
2016). In some photon radiation techniques (such as volumetric modulated arc therapy (VMAT)), large 










































































volumes of tissue receive low and intermediate radiation doses, which have shown to impact the 
circulating lymphocyte population (Tang et al., 2014). High-grade RIL has been widely associated with 
poor overall survival, disease recurrence, occurrence of distant metastases, and reduced pathologic 
complete response rates in a variety of tumors (Grassberger et al., 2019). 
Proton therapy differs from photon therapies in the distribution of the low dose bath to the body outside 
of the planned treatment volume and also in the treatment delivery time within a fraction. Figure 12a 
highlights the dosimetric differences for an intracranial tumor treated with either photon and proton 
therapy, which causes differences in dose to circulating lymphocytes (Fang et al., 2018; Ko et al., 2018). 
In studies on esophageal cancer it has been shown that patients treated with proton therapy have a >50% 
lower probability of developing grade 4 RIL compared to patients treated with IMRT (Routman et al., 
2019), an endpoint correlated to overall survival (Davuluri et al., 2017). Due to the lower integral dose, 
patients treated with protons had ~70% less grade 4 RIL compared to IMRT. However, this does depend 
both on target location relative to major vessels as well as differences in integral dose, and was not 
observed in a study of 150 patients with oropharyngeal cancer (Jensen et al., 2017).  
In addition to the radiation therapy modality, fractionation also affects the dose to the blood and the 
lymphocytes, thus possibly impacting outcome (Plowman, 1983; Crocenzi et al., 2016; Ko et al., 2018). 
Lymphocyte sparing radiation therapy was suggested because stereotactic body radiation therapy 
resulted in significantly less RIL in pancreatic cancer (Wild et al., 2016) and liver cancer (Gustafson et 
al., 2017). Smaller target volumes and hypofractionated regimens may be associated with higher post-
treatment lymphocyte counts. It has been estimated that during a conventional 30-fraction treatment with 
2 Gy/fraction to an 8-cm diameter planning target volume, 95% of circulating blood receives >0.5 Gy 
with a mean dose to circulating blood of >2 Gy (Wild et al., 2016) (Figure 13). Field size and dose rate 
effects on lymphopenia for solid tumors have been explicitly studied (Ellsworth, 2018). Not only dose 
to circulating lymphocytes but also dose received by tumor infiltrating lymphocytes, bone marrow, the 
lymphatic system and other lymphocyte reservoirs need to be considered. 
 
Figure 12: a, left: Treatment plans for an intracranial tumor (left: IMRT; right: proton therapy). b, right: 
Schematic illustration of the dose rate during a typical treatment for passively scattered proton therapy 
(red) and photon therapy (blue). 










































































Figure 13: Lymphocyte sparing in pancreatic cancer using 
conformal treatments (Wild et al., 2016) (with 
permission). 
In addition to radiation therapy impacting immune 
response, it also interacts with immune therapies. As 
radiation therapy has both local and systemic effects on 
the immune system, the combination of radiation therapy 
with immunotherapy represents a potential tool to 
maximize immune response and thus the efficacy of 
immune therapies (Kalbasi et al., 2013; Salama et al., 2016; Seyedin et al., 2015; Wang et al., 2018; 
Vatner et al., 2014).  
Current and Future Challenges 
Particularly in terms of tumor response, it is important to understand the interaction of protons with those 
drugs that target specific DNA damage or repair pathways. For instance, drugs can provide tumor cell 
selective radiosensitization to be combined with radiation therapy (Morgan and Lawrence 2015). As 
discussed in the section on “Relative Biological Effectiveness” the proton RBE depends on DNA repair 
pathways and as such also the interaction of protons with drugs targeting DNA damage or repair can 
influence the RBE. Similarly, new agents that have overlapping toxicities with radiation have to be 
studied carefully to confirm the validity of toxicity response models, for example pneumonitis in the 
case of immune checkpoint inhibitors with thoracic radiation therapy (Hwang et al. 2018). 
In addition to standard cytotoxic agents, the efficacy of proton therapy has to be analyzed in the context 
of immune therapies. Clinical data indicate that the low dose bath does affect the degree of RIL (Rudra 
et al., 2018). On the other hand, it has been suggested that low dose whole-body irradiation might 
improve outcome after subsequent treatment regimens due to radiation induced antigen release (Liu et 
al., 2010). In addition to dose-volume considerations, a faster rate of irradiation enables a larger fraction 
of circulating lymphocytes to be spared. The proportion of lymphocytes in circulation, and consequently 
at risk of being irradiated, might dictate the degree of systemic immune exposure. This is especially 
important for tumors that are close to major vessels, such as esophageal or centrally located lung cancers. 
Figure 12b illustrates dose rates to a voxel close to the target for a 7-field IMRT, a VMAT, and a 
passively scattered proton therapy plan. Intensity modulated proton therapy with its high degrees of 
freedom might offer new approaches to treatment optimization in the context of immune response or 
immunotherapies.  
To better understand the effect of the radiation dose bath on the immune system, we need more data on 
the presumably high relative radiosensitivity of lymphocytes in terms of cell kill and functional 
inactivation (Vandevoorde et al., 2016; Radojcic and Crompton, 2001). The impact of radiation not only 
on circulating lymphocytes but also on lymphatic vessels, tumor infiltrating lymphocytes and immune-
related signaling by normal tissues around the tumor needs to be better understood. Furthermore, 
predictive models of lymphocyte depletion rates and lymphocyte nadir as a function of dose distributions 
are needed to design clinical trials aiming at the optimal sequencing, prescribed dose, and fractionation 
of radiation with immunotherapy (Gunderson and Young, 2018; Ko et al., 2018). The role of proton 
therapy in this context is extensively being studied (Lee et al., 2018; Tsuboi, 2018; Ebner et al., 2017; 
Fang et al., 2018). 
The design of these clinical trials is challenging because of numerous potential combinations of 
systematic therapies, targeted therapies, immunotherapies, and radiation therapies. Furthermore, optimal 
combinations might depend on baseline patient characteristics, meaning that different immune 










































































landscapes might require different therapeutic approaches to achieve the highest probability of immune 
activation. Testing all potential arms in clinical trials is nearly impossible so that bio-mathematical 
modeling is becoming more important to guide clinical trial design (Enderling et al., 2019). 
Advances in Science and Technology to Meet Challenges 
Precision medicine in radiation oncology aims at defining parameters to identify patients that will benefit 
in terms of tumor control or normal tissue toxicities from specific modalities, e.g. cancer cells harboring 
certain defects in the DNA damage response are susceptible to proton therapy (see secton on 
“Biomarkers”). Mechanisms have to be analyzed also in the context of multi-modality therapies.  
Understanding the potential biological and immunological differences of proton therapy will reshape our 
understanding regarding the use of radiation therapy in general and proton therapy in particular. Based 
on immune response data from patients on clinical trials, we might develop novel plan optimization 
strategies to mitigate adverse immune-modulatory effects of radiation therapy. This requires assessment 
of patient specific immune response during and after RT, either via circulating biomarkers or advanced 
imaging techniques (Grassberger et al., 2019). This might ultimately lead to the establishment of 
personalized dose-volume constraints for immune structures and their inclusion in plan optimization. In 
this context proton therapy will have significant impact due to its dose-shaping capabilities combined 
with a low integral dose.  These constraints and predictive models will also allow for identification of 
patients at high risk of severe RIL who may benefit from proton therapy. Especially when used together 
with drugs modulating the patient’s immune response, a new planning paradigm might be required that 
takes the immune status of the patient into account, and ultimately treats the patient’s lymphocyte reserve 
as a radiosensitive organ at risk requiring accurate dose calculation.  
Concluding Remarks 
Proton therapy does interact differently with systemic therapies compared to photon therapies due to the 
reduced integral dose. In cases where radiation and systemic drugs target similar damage or repair 
pathways treatment plans may have to be optimized for combined modality treatments considering 
interaction terms. One prime example is the lymphocyte depletion due to the dose bath outside of the 
target. We are just beginning to understand the impact of radiation therapy on the immune system and 
the potential of radiation therapy in combination with immune therapies. Additional research is needed 
to assess if proton therapy leads to enhanced systemic preservation of antitumor immunity or whether a 
low dose bath might even help to trigger immune responses under certain circumstances. Enhancing not 
only our physical and biological but also our immunological understanding of proton therapy is critical 
to guide patient selection and to enhance the clinical effectiveness of proton therapy in combination with 
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